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Summary
Background Reliable and timely information on the leading causes of death in populations, and how these are 
changing, is a crucial input into health policy debates. In the Global Burden of Diseases, Injuries, and Risk Factors 
Study 2010 (GBD 2010), we aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 
235 causes, with uncertainty intervals (UIs), separately by age and sex.
Methods We attempted to identify all available data on causes of death for 187 countries from 1980 to 2010 from 
vital registration, verbal autopsy, mortality surveillance, censuses, surveys, hospitals, police records, and 
mortuaries. We assessed data quality for completeness, diagnostic accuracy, missing data, stochastic variations, 
and probable causes of death. We applied six diff erent modelling strategies to estimate cause-specifi c mortality 
trends depending on the strength of the data. For 133 causes and three special aggregates we used the Cause of 
Death Ensemble model (CODEm) approach, which uses four families of statistical models testing a large set of 
diff erent models using diff erent permutations of covariates. Model ensembles were developed from these 
component models. We assessed model performance with rigorous out-of-sample testing of prediction error and 
the validity of 95% UIs. For 13 causes with low observed numbers of deaths, we developed negative binomial 
models with plausible covariates. For 27 causes for which death is rare, we modelled the higher level cause in the 
cause hierarchy of the GBD 2010 and then allocated deaths across component causes proportionately, estimated 
from all available data in the database. For selected causes (African trypanosomiasis, congenital syphilis, whooping 
cough, measles, typhoid and parathyroid, leishmaniasis, acute hepatitis E, and HIV/AIDS), we used natural history 
models based on information on incidence, prevalence, and case-fatality. We separately estimated cause fractions 
by aetiology for diarrhoea, lower respiratory infections, and meningitis, as well as disaggregations by subcause for 
chronic kidney disease, maternal disorders, cirrhosis, and liver cancer. For deaths due to collective violence and 
natural disasters, we used mortality shock regressions. For every cause, we estimated 95% UIs that captured both 
parameter estimation uncertainty and uncertainty due to model specifi cation where CODEm was used. We 
constrained cause-specifi c fractions within every age-sex group to sum to total mortality based on draws from the 
uncertainty distributions.
Findings In 2010, there were 52·8 million deaths globally. At the most aggregate level, communicable, maternal, 
neonatal, and nutritional causes were 24·9% of deaths worldwide in 2010, down from 15·9 million (34·1%) of 
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46·5 million in 1990. This decrease was largely due to decreases in mortality from diarrhoeal disease (from 2·5 to 
1·4 million), lower respiratory infections (from 3·4 to 2·8 million), neonatal disorders (from 3·1 to 2·2 million), 
measles (from 0·63 to 0·13 million), and tetanus (from 0·27 to 0·06 million). Deaths from HIV/AIDS increased 
from 0·30 million in 1990 to 1·5 million in 2010, reaching a peak of 1·7 million in 2006. Malaria mortality also rose 
by an estimated 19·9% since 1990 to 1·17 million deaths in 2010. Tuberculosis killed 1·2 million people in 2010. 
Deaths from non-communicable diseases rose by just under 8 million between 1990 and 2010, accounting for two of 
every three deaths (34·5 million) worldwide by 2010. 8 million people died from cancer in 2010, 38% more than two 
decades ago; of these, 1·5 million (19%) were from trachea, bronchus, and lung cancer. Ischaemic heart disease and 
stroke collectively killed 12·9 million people in 2010, or one in four deaths worldwide, compared with one in fi ve in 
1990; 1·3 million deaths were due to diabetes, twice as many as in 1990. The fraction of global deaths due to injuries 
(5·1 million deaths) was marginally higher in 2010 (9·6%) compared with two decades earlier (8·8%). This was 
driven by a 46% rise in deaths worldwide due to road traffi  c accidents (1·3 million in 2010) and a rise in deaths from 
falls. Ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory infections, 
lung cancer, and HIV/AIDS were the leading causes of death in 2010. Ischaemic heart disease, lower respiratory 
infections, stroke, diarrhoeal disease, malaria, and HIV/AIDS were the leading causes of years of life lost due to 
premature mortality (YLLs) in 2010, similar to what was estimated for 1990, except for HIV/AIDS and preterm birth 
complications. YLLs from lower respiratory infections and diarrhoea decreased by 45–54% since 1990; ischaemic 
heart disease and stroke YLLs increased by 17–28%. Regional variations in leading causes of death were substantial. 
Communicable, maternal, neonatal, and nutritional causes still accounted for 76% of premature mortality in sub-
Saharan Africa in 2010. Age standardised death rates from some key disorders rose (HIV/AIDS, Alzheimer’s disease, 
diabetes mellitus, and chronic kidney disease in particular), but for most diseases, death rates fell in the past two 
decades; including major vascular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders. For 
other conditions, notably malaria, prostate cancer, and injuries, little change was noted.
Interpretation Population growth, increased average age of the world’s population, and largely decreasing age-specifi c, 
sex-specifi c, and cause-specifi c death rates combine to drive a broad shift from communicable, maternal, neonatal, and 
nutritional causes towards non-communicable diseases. Nevertheless, communicable, maternal, neonatal, and 
nutritional causes remain the dominant causes of YLLs in sub-Saharan Africa. Overlaid on this general pattern of the 
epidemiological transition, marked regional variation exists in many causes, such as interpersonal violence, suicide, 
liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others. Regional heterogeneity 
highlights the importance of sound epidemiological assessments of the causes of death on a regular basis.
Funding Bill & Melinda Gates Foundation.
Introduction
Cause-specifi c mortality is arguably one of the most 
fundamental metrics of population health. The rates and 
numbers of people who die, where, at what age, and 
from what, is a crucial input into policy debates, planning 
interventions, and prioritising research for new health 
technologies. Trends in causes of death provide an im-
portant geographical summary of whether society is or is 
not making progress in reducing the burden of pre-
mature (and especially avoidable) mortality and where 
renewed eff orts are needed. If a health information 
system is not providing timely and accurate information 
on causes of death by age and sex, major reforms are 
required to provide health planners with this essential 
health intelligence.
Despite the importance of tracking causes of death 
and the tradition since 1893 of standardisation of 
defi nitions and coding for causes of death in the 
International Classifi cation of Diseases and Injuries 
(ICD), global assessments of causes of death are a major 
analytical challenge. Vital registration systems that 
include medical certifi cation of the cause of death 
captured about 18·8 million deaths of an estimated 
annual total of 51·7 million deaths in 2005, which is the 
latest year for which the largest number of countries 
(100) reported deaths from a vital registration system. 
Even for these deaths, the comparability of fi ndings on 
the leading causes of death is aff ected by variation in 
certifi cation skills among physicians, the diagnostic and 
pathological data available at the time of completing a 
death certifi cate, variations in medical culture in choos-
ing the underlying cause, and legal and institu tional 
frameworks for govern ing mor tality report ing.1–5 For 
the remaining deaths that are not medically certifi ed, 
many diff erent data sources and diagnostic approaches 
must be used from sur veil lance systems, demographic 
research sites, surveys, censuses, disease registries, and 
police records to con struct a consolidated picture of 
causes of death in various populations. Because of the 
variety of data sources and their associated biases, cause 
of death assessments are inherently uncertain and 
subject to vigorous debate.6–8
Eff orts to develop global assessments for selected causes 
began in the 1980s.9–11 These eff orts were mo tivated partly 
because the sum of various disease-specifi c estimates 
substantially exceeded the estimated number of deaths in 
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the world, particularly for children.12 Lopez and Hull11 
attempted to develop a set of estimates of mortality in 
children younger than 5 years (under-5 mortality) by cause 
consistent with all-cause mortality data in 1983. The Global 
Burden of Disease study 1990 (GBD 1990) was the fi rst 
comprehensive attempt to do so, and included 134 causes 
covering all age groups. The GBD 1990 cause of death 
approach was applied with some refi nements to yield 
estimates of causes of death for 1999, 2000, 2001, 2002, 
2004, and 2008.13–17 Over this period, special attention was 
paid to priority diseases such as malaria, HIV/AIDS, and 
tuberculosis. The Child Health Epidemiology Reference 
Group (CHERG) also produced estimates of under-5 
mortality from 16 causes that summed to estimates of 
deaths in children younger than 5 years for 2000–03, 2008, 
and 2010,18–20 partly using the GBD 1990 approach com-
bined with other methods, and putting special emphasis 
on the use of verbal autopsy as a source of data in low-
income settings. Additionally to these com prehensive 
approaches, the tradition of disease-specifi c analyses that 
began in the 1980s with global cancer mortality has 
continued and intensifi ed. In the past 5 years, for example, 
articles and reports have been published on global 
mortality from maternal causes,21–24 malaria,25,26 tuber-
culosis,27,28 HIV/AIDS,29 road traffi  c accidents,30 site-specifi c 
cancers,31,32 and diabetes,33 among others.34,35 These 
assessments of individual causes are based on diverse 
epidemiological approaches of varying scientifi c rigour, 
and, moreover, are not constrained to sum to estimates of 
all-cause mortality from demographic sources.
Global cause of death assessments can be characterised 
in four dimensions: the universe of raw data identifi ed and 
examined, eff orts to evaluate and enhance quality and 
comparability of data, the statistical modelling strategy, 
and whether causes of death are constrained to sum to all-
cause mortality. First, in terms of the universe of data, the 
various iterations of the GBD and CHERG analysis of 
deaths in children younger than 5 years have made 
substantial use of data on causes of death from systems 
that attempt to capture the event of death. Other single-
cause analyses, such as the annual UNAIDS eff orts to 
estimate HIV-related deaths, measles estimates,34 the 
World Malaria Report,26 the WHO Global TB Control 
Report,28 and many others have used data on disease 
incidence or prevalence and on case-fatality rates combined 
in a model of natural history progression. Second, perhaps 
the area of greatest variation in the published studies is the 
eff orts to assess and enhance the quality and comparability 
of available data. These eff orts often include very specifi c 
steps undertaken for diff erent data sources and are fre-
quent ly poorly documented. Third, in the past two decades, 
eff orts to develop statistical models for causes of death 
have become more sophisticated. Compositional models 
that estimate cause fractions for several causes at once 
were fi rst applied to global health by Salomon and Murray36 
and have been used extensively by CHERG but only for a 
subset of causes. GBD revisions for 1999, 2000, 2001, 2002, 
2004, and 2008 have used these compositional models to 
allocate deaths according to three broad cause groups: 
communicable, maternal, neonatal, and nutritional 
causes; non-communicable diseases; and injuries. More 
recently, the array of modelling strategies used for causes 
of death has been broadened to include spatial-temporal 
Gaussian process regression,22,37 mixed eff ects hierarchical 
models, and ensemble models.38 Given the profusion of 
statistical modelling options, an important innovation has 
been the reporting of out-of-sample predictive validity to 
document the performance of complex models.22,38
Finally, in view of the developments in the fi eld of 
mortality and cause of death estimation, for the GBD 
2010 we completely re-evaluated all aspects of the GBD 
analytical strategy, including demographic estimation of 
all-cause mortality.39,40 Because of the huge increase in 
published verbal autopsy studies and the availability in 
the public domain of cause of death data from govern-
ment vital registration sources (130 countries), the 
universe of data has expanded substantially. Assessing 
and enhancing the quality and comparability of data can 
now take into account time trends in cause of death data 
from 1980 to 2010 that provide important insights into 
changes in certifi cation and coding. Borrowing from 
other scientifi c fi elds, we have changed our analytical 
approach (see below) to an ensemble modelling strategy 
to generate more realistic uncertainty intervals (UIs) and 
more accurate predictions.38 These innovations have 
been used in estimating mortality for an expanded GBD 
2010 cause list of 291 causes compared with 134 in the 
GBD 1990 Study; of the 291 causes, 235 are causes of 
mortality, whereas the remaining causes account for 
years lived with disability (YLDs) but not deaths. We use 
a unifi ed framework for all causes such that the sum of 
cause-specifi c estimates equals the number of deaths 
from all causes in each country or region, period, age 
group, and sex. This creates a link between the systematic 
analysis of data on all-cause mortality reported by Wang 
and colleagues40 and results by cause presented here. In 
this Article, we provide a summary overview of the vast 
array of data and methods that have gone into this 
revision of the GBD, as well as what we believe are the 
key global and regional fi ndings of importance for health 
priority debates.
Methods
Some general aspects of the analytical framework such as 
the creation of the 21 GBD regions and the full hierarchical 
cause list including the mapping of the ICD to the GBD 
2010 cause list are reported elsewhere.39 Although results 
are reported in this Article at the regional level for 1990 and 
2010, the cause of death analysis has been undertaken at 
the country level for 187 countries from 1980 to 2010. Use 
of longer time series improves the performance of many 
types of estimation models; data from before 1980, how-
ever, are much sparser for developing countries so we 
restricted the analysis to 1980–2010.
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Database development
Over the 5-year duration of the GBD 2010, we sought to 
identify all published and unpublished data sources 
relevant to estimating causes of death for 187 countries 
from 1980 to 2010. Depending on the cause, various 
sources of data were used. We briefl y outline in the 
following text the main types of data identifi ed and how 
they were used. The appendix (p 2) provides a summary of 
the site-years of data identifi ed by broad type of data system 
and the number of site-years by GBD region (the data 
presented in the appendix are mapped at the most detailed 
level for a given study; the aggregate levels are created by 
com bining the detailed levels). Of the GBD regions, central 
sub-Saharan Africa had the most limited evidence base 
with data on only 27 causes from at least one country.
For vital registration with medical certifi cation of causes 
of death, we identifi ed 2798 site-years of data from 
130 countries between 1980 and 2010. 3% of the site-years 
were coded with ICD 8, 44% with ICD 9, 40% with ICD 10, 
12% with country-specifi c tabulations of ICD 8, ICD 9, 
and ICD 10, and 1% with non-ICD tabulations. Addition-
ally, there is country to country variation in the detail used 
to report causes of death included in national reporting 
lists—namely, the basic tabulation list for ICD 9, the ICD 
10 tabulation list, three-digit and four-digit detail, and 
special reporting lists. Overall, we identifi ed 25 variants 
of cause of death reporting lists in use from 1980 to 
2010 across all sources of vital registration.
The verbal autopsy data were collected through sample 
registration systems, demographic surveillance systems, 
or surveys. Verbal autopsy is a means for ascertaining 
the cause of death of individuals and the cause-specifi c 
mortality fractions in populations with incomplete vital 
registration systems. A trained interviewer uses a struc-
tured questionnaire to ask about the signs, symptoms, 
and demographic characteristics of a recently deceased 
individual from the next of kin. We identifi ed 486 site-years 
of published and unpublished verbal autopsy data across 
66 countries, of which 10% were nationally repre sentative. 
Verbal autopsy data are highly heterogeneous: studies use 
diff erent instruments, diff erent cause lists from single 
causes to full ICD cause lists, diff erent methods for 
assigning cause of death based on a completed verbal 
autopsy, diff erent recall periods, and diff erent age groups, 
quite apart from cultural diff erences in the interpretation 
of specifi c questions. The appendix (p 25) provides a full 
listing of the sources used for all verbal autopsy and non-
vital registration data organised by country.
Population-based cancer registries provide an import-
ant source of data on incidence of cancers in various 
countries. We identifi ed 2715 site-years of cancer registry 
data across 93 countries. Some registries also track can-
cer mortality and provide plausible data on the mortality-
to-incidence ratio by age, sex, and site. Following the 
methods developed by Forouzanfar and colleagues,31 we 
developed estimated mortality-to-incidence ratios for all 
major cancers by age, sex, and country. We estimated the 
log of the mortality-to-incidence ratio as a function of 
national income per head with random eff ects for coun-
try, year, and age. The estimated mortality-to-incidence 
ratios were used to map cancer registry data on incidence 
to expected deaths that have been incorporated into the 
database. Mortality-to-incidence ratios by country, age, 
and sex are available on request.
In most countries, police and crime reports are an 
important source of information for some types of in-
juries, notably road injuries and interpersonal violence. 
The police reports used in this analysis were obtained 
from published studies, national agencies, and insti-
tutional surveys such as the UN Crime Trends survey 
and the WHO Global Status Report on Road Safety 
Survey.30,41 By comparing with other sources such as vital 
registration data, we assessed whether police reports 
were likely to be complete and cover the entire country. 
In total, we included in the analysis 1129 site-years of 
police reports from 122 countries from 1980 to 2010 that 
met our criteria.
We identifi ed 32 site-years of burial and mortuary data 
in 11 countries from ministries of health, published 
reports, and mortuaries themselves. Because of known 
bias in the epidemiological composition of burial and 
mortuary data, we only used information on the fraction 
of injuries due to specifi c sub-causes from these sources. 
These proportionate fractions of injury deaths due to 
specifi c causes were transformed into fractions of all 
causes by multiplying by the fraction of all deaths due to 
injuries estimated from a model for all injuries.
Multiple demographic and health surveys, other sur-
veys, and censuses provide data on the fraction of deaths 
in the reproductive age groups that are pregnancy-
related. We identifi ed 1557 survey years with sibling 
history data, and a further 52 household survey years or 
census years of data covering 61 countries. We also iden-
tifi ed 56 surveys or censuses with information on injury 
mortality across 65 survey years or census years.
We identifi ed eight countries with nationally represen-
tative maternal mortality surveillance systems covering 
83 site-years and fi ve GBD regions. Some surveillance 
systems were based on prospective verbal autopsy. Sur-
veillance data on the number of maternal deaths, or the 
maternal mortality ratio multiplied by births, were con-
verted into cause fractions by dividing by the total number 
of deaths estimated in the reproductive age groups.
Additionally, we included 21 site-years of data based on 
deaths in health facilities. However, we chose to only 
incor porate deaths due to injury from this source because 
of known bias. We adjusted data for bias using a revised 
version of the hospital adjustment method, which uses 
more data and is more consistent with the GBD cause 
list developed by Murray and colleagues in 2007.42 This 
method attempts to correct for selection bias in the 
deaths that occur in hospital. Finally, we used only the 
fraction of injury deaths due to specifi c injuries from 
these sources and converted them to fractions of deaths 
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from all causes following the method described for burial 
and mortuary data.
Assessement and enhancement of data quality and 
comparability
We assessed and enhanced data quality following six 
steps outlined in more detail here:
Step 1 consists of the assessment of completeness of 
death recording in each source. In settings where a data 
source does not capture all deaths in a population, the 
cause composition of deaths captured might be diff erent 
from those that are not. Murray and Lopez43 postulated in 
the GBD 1990 that deaths recorded in countries with 
incomplete vital registration would more likely originate 
from wealthier sectors of populations for which the 
cause of death structure was skewed towards non-
communicable rather than communicable diseases, 
com municable diseases being more common in those 
who cannot aff ord appropriate treatment. They proposed 
a correction based on the assumption that this inequality 
in death rates within a country was uniform across 
countries. This approach was used in subsequent GBD 
revisions and in some of the CHERG19,44 analyses when 
making use of vital registration data.
There are reasons, however, to also be concerned that 
deaths recorded in systems with low coverage might be 
biased towards selected causes that are more likely to 
occur in hospital. Many vital registration systems begin 
with in-hospital deaths and progressively capture deaths 
in the community. Murray and colleagues42 showed that 
the fraction of deaths in hospital was higher for acute 
causes for which death was not immediate but occurred 
over a matter of days such as for some maternal causes. 
Further, evidence on subnational mortality patterns45 
clearly shows that the assumption of uniform inequality 
is unlikely to be true; nor is the assumption that deaths 
are registered in order, from the richest to the poorest 
communities. For the GBD 2010, we assessed the com-
pleteness of vital registration or sample registration data 
over age 5 years using the most accurate variants of death 
distribution methods: synthetic extinct gener ations, the 
generalised growth balance method, and a hybrid of the 
two.46 We assessed completeness for under age 5 years by 
comparing registration data with survey and census data 
on child mortality. More details on how the synthesis of 
these methods was done are provided by Wang and 
colleagues.40 Completeness is often substan tially diff erent 
for child and adult deaths; in some regions such as Latin 
America, child completeness is usually lower than adult 
completeness, but other pat terns are observed in Asia.40 
Completeness levels must also be interpreted with 
caution. Some systems, for example in Turkey, capture 
deaths relatively completely in selected administrative 
units only. That is, complete ness of registration might be 
high but coverage is not.
For adults, few vital registration or sample registration 
datapoints exist with completeness lower than 70% in the 
database. Because completeness is often lower for deaths 
in children younger than 5 years compared with that in 
individuals older than 5 years, we investigated the eff ect of 
including data on causes of death with com pleteness lower 
than 70% (see appendix p 49 for more detail). We re-ran 
cause of death models for the major causes of death in 
children younger than 5 years in fi ve diff erent ways: 
excluding all data with completeness lower than 30%, 
lower than 40%, lower than 50%, lower than 60%, and 
lower than 70%. At the global level, the number of deaths 
estimated in 2010 for acute respiratory infections and diar-
rhoea, for example, diff er by 0·9% and 1·2%, respectively, 
between models that include all data and those that exclude 
data where death registration for children younger than 
5 years is less than 70% complete. The diff erence is slightly 
larger in 1980, for which including all data leads to higher 
numbers than excluding the incomplete data. Even in the 
1980s at the regional or country level, the diff erences are 
small enough that we chose to use all available data. These 
sensitivity analyses suggest that, at least for major causes 
of child death, no consistent evidence of selection bias 
towards causes of death in richer populations exists.
To assess completeness is feasible for vital registration 
and sample registration data but not for small-scale studies 
on verbal autopsy, which might not detect all deaths 
through household recall. In fact, household recall often 
yields a substantial undercount of deaths.47,48 In the absence 
of evidence on the cause of death pattern in recalled versus 
not recalled deaths, we have made the simplifying assump-
tion that verbal autopsy cause fractions are repre sentative 
of the study population; the CHERG analyses of verbal 
autopsy data make the same assumption.19,20
Step 2 consists of mapping revisions and variants of the 
ICD (see appendix p 50 for more detail). Vital registration 
data and some verbal autopsy data for 1980–2010 are 
reported using several variants of the ICD 8, ICD 9, and 
ICD 10. We mapped these revisions to the GBD cause list 
in the appendix. This mapping provides the codes for the 
detailed list for ICD 9 and ICD 10, as well as the basic 
tabulation list for ICD 9 (BTL). We identifi ed three 
national variants of ICD 9 BTL that we also mapped to the 
GBD cause list. Of note, there were 119 GBD causes not 
available in the BTL, such as pneumonia and diarrhoea 
aetiologies, some of the cancers, hepatitis by type, some of 
the cardio vascular causes, many of the mental and 
behavioural disorders, some musculoskeletal disorders, 
and some injury subtypes.
Step 3 relates to the redistribution of deaths assigned to 
garbage codes. Murray and Lopez43 introduced the notion 
of “garbage codes” in the GBD 1990 and proposed methods 
to redistribute deaths assigned to garbage codes to 
probable underlying causes of death. Garbage codes are 
causes of death that should not be identifi ed as underlying 
causes of death but have been entered as the underlying 
cause of death on death certifi cates. Classic examples of 
garbage codes include senility or cardiopulmonary arrest. 
In the GBD 1990, major garbage codes were identifi ed and 
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simple algorithms proposed to redistribute these pro-
portionately to various causes (called “target codes”) that 
were the likely underlying causes of death.49 A similar 
approach was applied for the GBD 2000 and subsequent 
WHO updates. For the GBD 2010, we identifi ed causes 
that should not be assigned as underlying cause of death 
at a much more detailed level.50 In total, we identifi ed 
2759 garbage codes in ICD 10 detailed data, 3382 garbage 
codes in ICD 9 detailed data, and 85 garbage codes in the 
ICD 9 BTL, ranging from abdominal rigidity to yellow nail 
syndrome. Garbage codes have been identifi ed at the most 
detailed level possible (eg, the fourth digit level for ICD 9 
and ICD 10). For every garbage code, the potential under-
lying causes of death were identifi ed on the basis of patho-
physiology. For example, the target codes for peri tonitis 
included acute gastric ulcers with perforation and acute 
tubulo interstitial nephritis; the target codes for dis-
seminated intravascular coagulation included other septi-
caemia and premature separation of placenta. More over, 
redistribution proportionate to the number of deaths noted 
in the target codes cannot be reliably applied; for example, 
although many injuries exist, not all peritonitis deaths are 
likely due to injuries. Similarly, the probability of deaths 
due to a target cause being mis classifi ed on death certifi -
cates as a garbage code is not equal. We have developed 
allocations of the garbage codes on the basis of the little 
published scien tifi c literature, expert judgment, statistical 
analysis,51 and in some cases proportionate allocation 
across target causes. The appendix (pp 71–103) provides a 
complete listing of the redistribution algo rithms used, 
organised by garbage code. The extent of garbage coding in 
vital registration data varies widely across countries from a 
low of 5·5% in Finland to a high of 69·6% in Sri Lanka.
Step 4 consists of age splitting and age-sex splitting. 
Sources report data according to varying age groups; for 
consistency in the analysis, the GBD project defi ned and 
used a standardised set of 20 age groups throughout. 
Data reported for more aggregate age groups are split into 
estimates of age-specifi c deaths using the global observed 
pattern of relative risks of death for a cause by age and the 
local distribution of the population by age. Relative risks 
of death by age were computed for each cause using the 
entire pooled dataset on medically certifi ed causes of 
death. In the few cases in which studies reported deaths 
for both sexes combined, a similar approach was used to 
allocate these deaths to age-sex groups. The appendix 
(p 104) provides more detail on the development of the 
age splitting model and the age-sex splitting model.
Step 5 consists of smoothing. For some causes in some 
countries, the number of deaths observed in a year is very 
low; zero, one, or two deaths might be noted in some years 
because of stochastic fl uctuation. For models using the log 
of the death rate, either observations that record zero 
deaths are dropped or an arbitrary small number is sub-
stituted for zero observations; both ap proaches can lead to 
bias. This issue is exacerbated in modelling strategies 
that attempt to capture spatial and temporal correlation 
structure. In cases for which many years for a country-
cause-age group did not report any deaths, we used a 
standardised smoothing algorithm, essentially a type of 
moving average, as described in the appendix (p 104).
Step 6 consists of outlier detection. Despite these 
eff orts to enhance quality and comparability, the data 
from some sources seem completely implausible. Where 
these sources are one of many in a country for a given 
cause, they have little eff ect on the results. In some cases, 
however, time series estimation can be substan tially 
aff ected by these outliers. We identifi ed outliers that met 
the following criteria: large inconsistency with other data 
for the same cause in the same country at the same time; 
large inconsistency with other data for similar countries; 
or disproportionate eff ect on time series estimation. 
In these cases, the observation was excluded from sub-
sequent analysis. The interpretation of large incon-
sistency or disproportionate eff ect varies by cause and 
was based on the consensus of the investigators.
Modelling of individual causes of death
We used six diff erent modelling strategies for causes of 
death depending on the strength of the available data. 
The appendix (p 105) shows the modelling strategy used 
for each cause; in the table, “aggregation” means that 
the parent cause in the hierarchy is simply the sum of 
the causes under that rubric. In the following section, 
we provide additional detail on the diff erent modelling 
strategies used. All of the strategies, however, were 
designed to generate un certainty distributions for the 
cause-specifi c death rate by age, sex, country, and year. 
We attempted to capture uncertainty due to model 
parameter estimation, model specifi cation, and funda-
mental uncertainty. For Cause of Death Ensemble 
Modelling (CODEm), the validity of uncertainty dis-
tributions were assessed. The uncertainty dis tribution 
for a cause for a given country, year, age, and sex group 
from the modelling process is propagated into compu-
tation of years of life lost because of premature mortality 
(YLLs) and various geographic and age-sex aggregates 
by sampling 1000 draws from the posterior distribution.
CODEm
For all major causes of death except for HIV/AIDS and 
measles, we used CODEm—133 causes in the cause list 
and three other special aggregates. CODEm was used to 
analyse maternal mortality, breast and cervical cancer 
mortality, and malaria mortality in published stud ies.22,25,31 
The logic and development of CODEm is reported in 
detail elsewhere.38 In brief, CODEm develops models 
following three steps:
First, a large range of plausible statistical models 
are developed for each cause. Based on published studies, 
plausible relationships between covariates and the 
relevant cause are identifi ed. Essentially all possible 
permutations of these selected covariates are tested. All 
models where the sign on the coeffi  cient for a covariate is 
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in the direction expected based on the literature and the 
coeffi  cient is statistically signifi cant are retained. Where 
there are n covariates, this means testing 2n models. 
Additionally, four families of statistical models are 
developed using covariates: mixed eff ects linear models 
of the log of the death rate, mixed eff ects linear models of 
the logit of the cause fraction, spatial-temporal Gaussian 
process regression (ST-GPR) models of the log of the 
death rate, and ST-GPR of the logit of the cause fraction. 
Finally, ensemble models, or blends of these various 
component models, are developed.
Second, the performance of all component models 
and ensembles is evaluated using out-of-sample pre-
dictive validity tests. 30% of the data is excluded from 
the initial model fi ts; half of that (15% of total) is used to 
evaluate component models and build ensembles. Out-
of-sample predictive validity tests are based on com-
paring predic tions for the remaining 15% of the data 
withheld from the model-building exercise with the 
actual observed data. Data are held out from the analysis 
using the pattern of missingness for each cause in the 
cause of death database. For example, if there are 
countries with no data, then the algorithm will exclude 
all data for some countries; if some countries only have 
data for children, then the algorithm will exclude all 
adult data for some countries. In this way, the out-of-
sample predictive validity testing mimics the task 
required of a good cause of death model. The out-of-
sample predictive validity testing is repeated until stable 
model results have been obtained. Tests of out-of-
sample per formance include the root-mean squared 
error of the log of the cause-specifi c death rate, the 
direction of the trend in the prediction compared to the 
data, and the validity of the 95% UI.
Third, on the basis of out-of-sample predictive validity, 
the best performing model or ensemble is selected. 
The rigorous evaluation of out-of-sample performance 
means that for every CODEm model, we generate 
objective data on the validity of the resulting UIs.
The appendix (p 112) summarises the performance of 
the CODEm models developed for 133 causes in the 
cause list for which we exclusively use CODEm and 
three special aggregates in the GBD 2010. For some 
causes, separate models were run for diff erent age 
ranges when there was reason to believe that the 
relation between covariates and death rates might be 
diff erent in diff erent age ranges, for example, in 
children compared with adults. For every model, we 
show the in-sample root mean squared error of the log 
death rates (RMSE) and the out-of-sample per formance 
in the 15% of data not used in the model building 
process. In all cases, the out-of-sample per formance is 
worse (larger RMSE) than the in-sample performance. 
Of note, the gap between in-sample and out-of-sample 
performance varies sub stan tially across causes— from 
mechanical forces (fi re arm) with the largest diff er-
ence to leukaemia with the small est. Out-of-sample 
performance also varies substantially across causes; 
kidney cancer has the largest RMSE in female indiv-
iduals (2·039) and the smallest RMSE is for car dio-
vascular and circulatory disease in male indiv iduals 
(0·555). More than 50% of the models the appendix 
(p 112) have an out-of-sample RMSE of less than 1. The 
next columns provide the assessment of how often the 
model predicts the trend from year to year observed in 
the data. Because of stochastic fl uctuation in death 
rates, we do not expect a good model to predict the 
trend observed in the data 100% of the time. The gap 
between in-sample and out-of-sample trend test is less 
notable than the gap for the RMSE. The fi nal assessment 
of model performance is the validity of the UIs; ideally, 
the 95% UI for a model would capture 95% of the data 
out-of-sample. Higher coverage suggests that UIs are 
too large and lower than 95% suggest UIs are too 
narrow. Coverage across the CODEm models ranges 
from 99·0% for “other neuro logical disorders” to a low 
of 84·2% for pneumoconiosis.
Negative binomial models
For 27 causes, the number of deaths recorded in the 
database was too low to generate stable estimates of 
out-of-sample predictive validity. For these causes, we 
developed negative binomial models using plausible 
covariates. These causes are identifi ed in the appendix 
(p 105). For these negative binomial models, standard 
model building practice was followed, where plausible 
covariates were included in the model development and 
reverse stepwise procedures followed for covariate 
inclusion. Uncertainty distri butions were estimated 
using both uncertainty in the regression betas for the 
covariates and from the gamma distribution of the 
negative binomial.
Fixed proportion models
In 27 causes where death is a rare event, we fi rst 
modelled the parent cause in the GBD hierarchy using 
CODEm and then allocated deaths to specifi c causes 
using a fi xed proportion. Proportions were computed 
using all available data in the database and were fi xed 
over time, but, depending on data density, allowed to vary 
by region, age, or sex. Specifi cally, uterine fi broids, poly-
cystic ovarian syndrome, endometriosis, genital pro lapse, 
and other gynecological disorders varied by region and 
age for female individuals. Lower respiratory infections, 
upper respiratory infections, meningitis, and encepha-
litis varied by region and age. Thalassaemia, sickle-cell 
disease, glucose-6-phosphate dehydrogenase (G6PD) 
defi ciency, and other haemoglobinopathies and haemo-
lytic anaemias vary in proportion by country, age, and sex. 
Opioid, cocaine, amphetamine, and other drug use 
disorders varied by region and year. Finally, cellulitis, 
decubitus ulcer, other skin and subcutaneous diseases, 
abscess, impetigo, and other bacterial skin diseases all 
varied by age and sex.
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Diarrhoea, lower respiratory infection, meningitis, cirrhosis, 
maternal disorders, liver cancer, and chronic kidney disease 
disaggregated by subcause
The GBD 2010 cause list includes ten aetiologies for diar-
rhoea, fi ve for lower respiratory infections, and four for 
meningitis. Additionally, we included a breakdown of 
maternal causes, cirrhosis, liver cancer, and chronic 
kidney disease by subcause. In most of these cases, 
published data are available on the cause or primary 
diagnosis for community, hospital, or registered cases, but 
not for deaths. For these causes, systematic reviews of the 
published data and careful review of statistical annuals 
such as renal registries have been undertaken. These 
studies or datapoints on aetiology were meta-analysed 
using the GBD Bayesian meta-regression method 
described elsewhere.52 The meta-regression generated 
region-age-sex estimates with uncertainty of causal 
fractions for diarrhoea, lower respiratory infections, 
meningitis, chronic kidney disease, maternal disorders, 
cirrhosis, and liver cancer (appendix pp 121–129). These 
fractions were then applied to estimates of the parent 
cause, which were estimated using CODEm. In the cases 
of cirrhosis, liver cancer, maternal disorders, and chronic 
kidney disease, the studies or datasets on cause identifi ed 
primary cause as assessed clinically; for diarrhoea, lower 
respiratory infections, and meningitis, cause was based 
on laboratory fi ndings.
Natural history models
For a few selected causes, there is evidence that cause of 
death data systems do not capture suffi  cient information 
for one of two reasons. First, for some causes such as 
African trypanosomiasis, almost no deaths are recorded 
in vital registration or verbal autopsy studies, most likely 
because data have not been obtained in focal populations 
with substantial disease present. Second, there is sys-
tematic misclassifi cation of deaths in cause of death data 
sources, particularly for congenital syphilis,53,54 whooping 
cough,55 measles,56 and HIV/AIDS.57 For these causes, 
natural history models have been used that begin with 
data on incidence or prevalence of disease and case-
fatality rates (appendix pp 129–141). In the case of 
HIV/AIDS, a hybrid approach was used. For 36 countries, 
with complete and high quality vital registration systems, 
we used CODEm, in consultation with UNAIDS. For the 
remaining countries, we used the estimates with 
uncertainty by age and sex provided directly by UNAIDS 
based on their 2012 revision. In the case of Thailand and 
Panama, however, UNAIDS 2012 revision estimates are 
considerably higher than 2010 estimates and are 
inconsistent with the all-cause mortality evi dence. For 
these two countries, we used the 2010 UNAIDS revision.
Mortality shock regressions
To estimate deaths directly due to natural disasters or 
collective violence, we used a diff erent approach. First, 
we developed a variable for reported battle and disaster 
deaths per 10 000 using various databases for both 
disasters and collective violence; next, we estimated the 
empirical relation between under-5 mortality and mor-
tality in adults (45q15) and this variable in settings where 
data were collected during these mortality shocks. As a 
fi nal step, we used this empirical relation observed in 
periods of mortality shocks along with detailed data by 
age to allocate deaths due to natural disasters and 
collective violence by age. Details of this approach are 
outlined by Murray and colleagues.58
To develop the covariate on battle deaths during col-
lective violence, we used data from the Armed Confl ict 
Database from the International Institute for Strategic 
Studies (1997–2011), the Uppsala Confl ict Data Program 
(UCDP)/PRIO Armed Confl ict Dataset (1946–present), 
and available data from complete vital registration systems. 
In country-years where estimates are available from more 
than one source, priority is given to vital registration data if 
it gives higher estimated deaths. When vital registration 
data are not available, priority is given to the Uppsala 
Confl ict Data Program (UCDP)/PRIO Armed Confl ict 
Dataset since it has much longer and more consistent time 
series of estimates. The covariate for deaths due to natural 
disaster is based on the International Disaster Database 
(Centre for Research on the Epidemiology of Disasters).59–61
The relations between under-5 mortality and adult 
mor tality and the disaster and collective violence 
All causes Communicable, 
maternal, neonatal, and 
nutritional disorders
Non-communicable 
diseases
Injuries 
1990 deaths (thousands) 46 511 15 859 26 560 4092
Deaths expected with 2010 population, 1990 population age structure, 1990 death rates (thousands) 61 307 23 295 32 647 5365
Deaths expected with 2010 population, 2010 population age structure, 1990 death rates (thousands) 70 316 21 513 43 062 5741
2010 deaths (thousands) 52 770 13 156 34 540 5073
Percentage change from 1990 due to population growth 31·8% 46·9% 22·9% 31·1%
Percentage change from 1990 due to population ageing 19·4% –11·2% 39·2% 9·2%
Percentage change from 1990 due to change in death rates –37·7% –52·7% –32·1% –16·3%
Percentage change from 1990 to 2010 13·5% –17·0% 30·0% 24·0%
Table 1: Decomposition analysis of the change of global death numbers (thousands) by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes 
in age-specifi c, sex-specifi c, and cause-specifi c death rates
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covariates were estimated using 43 empirical observations 
for disasters and 206 empirical observations for collective 
violence (only years with crude death rates from shocks 
of more than one per 10 000 were kept in this analysis). 
The relation was estimated for excess mortality from 
these data sources by fi rst subtracting from observed 
mortality rates the expected death rates in shock years 
with the methods outlined by Murray and colleagues.58 
The coeffi  cients from these regressions and the disaster 
and collective violence covariates were used to predict 
excess deaths from these two causes. Because these 
models take into account competing causes by estimating 
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War and disaster
Intentional injuries
Unintentional injuries
Transport injuries
Other non-communicable 
diseases
Musculoskeletal disorders
Diabetes, urogenital, 
blood, and endocrine
Mental and behavioural
disorders
Neurological disorders
Digestive diseases
Cirrhosis
Chronic respiratory
diseases
Cardiovascular and
circulatory diseases
Cancer
Other communicable
diseases
Nutritional deficiencies
Neonatal disorders
Maternal disorders
Neglected tropical 
diseases and malaria
Diarrhoea, lower 
respiratory infections, 
and other common 
infectious diseases
HIV/AIDS and tuberculosis
Figure 1: Percentage of global deaths for female and male individuals in 1990 and 2010 by cause and age
(A) Male individuals, 1990. (B) Female individuals, 1990. (C) Male individuals, 2010. (D) Female individuals, 2010. An interactive version of this fi gure is available online at http://
healthmetricsandevaluation.org/gbd/visualizations/regional.
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the relation between excess mortality and these co-
variates, we did not subject estimates for these two 
causes to the CoDCorrect algorithm described in the 
following text. The age pattern of mortality from these 
mortality shocks is based on the relative age pattern of 
mortality observed in the empirical data from functioning 
vital registration systems.
Combining results for individual causes of death to 
generate fi nal estimates—CoDCorrect algorithm
Because we had developed single-cause models, it was 
imperative as a fi nal step to ensure that individual cause 
estimates summed to the all-cause mortality estimate 
for every age-sex-country-year group. This had to be 
done taking into account uncertainty in every cause of 
death model outcome, where some causes were known 
with much greater precision than others. We used a 
simple algorithm called CoDCorrect; at the level of each 
draw from the posterior distribution of each cause, we 
pro portionately rescaled every cause such that the sum 
of the cause-specifi c estimates equalled the number of 
deaths from all causes generated from the demo-
graphic analysis.40
In practice, a random draw without replacement was 
taken from the posterior distribution of 1000 draws for 
each cause and matched to a draw from the all-cause 
mortality distribution for that age-sex-country-year. We 
assumed that if the sum of deaths from each individual 
cause was large, it was more likely to be associated with a 
higher draw of the all-cause mortality level. To refl ect 
this, we induced a rank order correlation of 1·0 between 
the sum of the random draws across causes and the 
all-cause mortality level. The eff ect of this rank order 
correlation was to increase the uncertainty in the fi nal 
estimates for every cause in countries where substantial 
uncertainty existed in the level of all-cause mortality.
Repeated simulation studies show that the two-stage 
approach used here—namely, modelling each cause 
individually and then applying the CoDCorrect algo-
rithm, gives high levels of cause-specifi c mortality 
fraction accuracy (appendix pp 146–148). These simu-
lation studies also show that, under all circum stances 
tested, the two-stage approach to cause of death model-
ling is as good as or better than a single-stage approach 
as proposed by Salomon and Murray.36
We applied CoDCorrect in a hierarchical way. The 
appendix (pp 106–110) identifi es three levels of appli-
cation of CoDCorrect. We fi rst applied the algorithm for 
level 1 causes. We then applied CoDCorrect for level 2 
causes such that the sum of level 2 causes for a country-
year-age-sex group equalled the draws of the level 1 
cause. This cascade was repeated for level 3 causes. We 
chose levels for each cause based on consideration of 
the amount and quality of available data. For example, 
because there were substantially more data on all 
cardiovascular causes from verbal autopsy studies than 
for specifi c cardiovascular causes, we designated “all 
cardiovascular” as a level 1 cause for CoDCorrect. 
Another example of this approach is for the category 
“chronic respiratory diseases” where there was sub-
stantially more data for the aggregate cause than for 
chronic obstructive pulmonary disease (COPD), asthma, 
pneumoconiosis, and interstitial lung disease. Since we 
only wanted to group causes at level 2 or level 3 that 
were strongly related with common determinants, we 
did not use higher level aggregates such as “all non-
communicable diseases” as level 1 causes because it was 
diffi  cult to develop plausible models for these groups 
that included some causes that were increasing and 
others that were decreasing in the same time period.
The appendix (p 144) shows the percentage change in 
every cause of death for 2010 due to the application of 
CoDCorrect to level 1 causes at the global level. This 
provides a rough metric of how much inconsistency 
there is between models for specifi c causes of death and 
the demographic analysis. Although at the draw level the 
same scalar was applied to all causes, the net eff ect of 
CoDCorrect was to change the size of more uncertain 
causes by more than is done for more certain causes, a 
desirable property.
Ranking lists
For the presentation of leading causes of death, the level 
at which one ranks causes is subject to debate. Given the 
GBD cause list tree structure, many options are possible, 
such as all cancers versus site-specifi c cancers. We opted 
to produce tables of rankings using the level of dis-
aggregation that seemed most relevant for public health 
decision making. Although we report more disaggre gated 
causes, because of considerations related to public health 
pro gram mes, we chose to include diarrhoeal diseases, 
lower respiratory infections, maternal causes, cerebro-
vascular disease, liver cancer, cirrhosis, drug use, road 
injury, exposure to mechanical forces, animal contact, 
homicide, and congenital causes in the ranking list.
Computation of YLLs due to premature mortality
YLLs are computed by multiplying deaths at each age by 
the reference standard life expectancy at that age. The 
reference standard has been constructed using the 
lowest observed death rate in each age group across 
countries with a population greater than 5 million (see 
Murray and colleagues39 for details). In practice, for 
deaths in a given age-interval such as 20–24 years, we 
used country-specifi c estimates from the demographic 
analysis of the mean age of death in that interval.40 In the 
GBD 2010, the terminal age group for the analysis of 
causes of death and YLDs is 80 years and older because 
of the scarcity and quality of data for older age groups. 
Because the all-cause mortality analysis was undertaken, 
however, for more detailed age groups up to age 
110 years, we were able to take into account the mean age 
of death over 80 years in every country-year-sex group in 
computing YLLs.
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All ages deaths (thousands) Age-standardised death rates (per 100 000)
1990 2010 %Δ 1990 2010 %Δ
All causes 46 511·2 (45 497·4–47 726·2) 52 769·7 (50 877·7–53 917·2) 13·5% 999·1 (979·2–1022·0) 784·5 (756·3–801·6) –21·5
Communicable, maternal, neonatal, and nutritional 
disorders
15 859·2 (15 065·8–16 842·5) 13 156·4 (12 377·2–13 807·6) –17·0% 271·1 (258·4–287·2) 189·8 (178·6–199·2) –30·0
HIV/AIDS and tuberculosis 1770·3 (1600·2–2032·7) 2661·4 (2358·1–2895·7) 50·3% 39·3 (35·4–45·2) 39·4 (34·8–42·9) 0·2
Tuberculosis 1471·5 (1318·5–1716·1) 1196·0 (923·7–1376·8) –18·7% 33·3 (29·8–38·7) 18·0 (13·9–20·7) –46·0
HIV/AIDS 298·8 (242·0–378·5) 1465·4 (1334·2–1606·0) 390·4% 6·0 (4·8–7·7) 21·4 (19·4–23·5) 258·4
HIV disease resulting in mycobacterial infection 53·8 (42·4–70·0) 256·9 (231·9–284·1) 377·2% 1·1 (0·8–1·4) 3·7 (3·4–4·2) 254·4
HIV disease resulting in other specifi ed or unspecifi ed 
diseases
245·0 (197·7–312·6) 1208·4 (1091·6–1333·9) 393·3% 4·9 (3·9–6·3) 17·6 (15·9–19·5) 259·3
Diarrhoea, lower respiratory infections, meningitis, 
and other common infectious diseases
7772·1 (7136·0–8769·2) 5276·9 (4742·2–5790·4) –32·1% 131·9 (122·4–146·5) 76·4 (68·6–83·7) –42·1
Diarrhoeal diseases 2487·4 (2306·8–2661·9) 1445·8 (1278·9–1607·0) –41·9% 41·0 (38·3–43·6) 20·9 (18·5–23·3) –49·0
Cholera 120·9 (96·7–149·1) 58·1 (44·2–74·3) –52·0% 1·8 (1·4–2·2) 0·8 (0·6–1·0) –54·5
Other salmonella infections 134·7 (107·5–162·4) 81·3 (61·8–101·7) –39·6% 2·3 (1·8–2·7) 1·2 (0·9–1·5) –48·2
Shigellosis 194·0 (161·5–227·4) 122·8 (97·4–149·6) –36·7% 3·3 (2·8–3·9) 1·8 (1·4–2·2) –46·5
Enteropathogenic E coli infection 205·5 (163·0–250·2) 88·7 (66·8–112·8) –56·8% 3·0 (2·4–3·6) 1·2 (0·9–1·6) –58·2
Enterotoxigenic E coli infection 184·0 (155·6–218·2) 120·8 (95·7–147·6) –34·4% 3·3 (2·7–3·9) 1·8 (1·4–2·2) –45·8
Campylobacter enteritis 210·8 (171·2–253·6) 109·7 (81·8–137·2) –48·0% 3·3 (2·7–4·0) 1·6 (1·2–2·0) –52·5
Amoebiasis 67·7 (53·2–82·8) 55·5 (40·6–73·8) –18·1% 1·4 (1·1–1·7) 0·8 (0·6–1·1) –39·0
Cryptosporidiosis 222·6 (181·5–264·7) 99·8 (76·1–125·0) –55·2% 3·2 (2·6–3·8) 1·4 (1·1–1·8) –56·6
Rotaviral enteritis 523·3 (433·5–605·7) 250·9 (191·5–308·2) –52·1% 7·9 (6·5–9·2) 3·6 (2·7–4·4) –54·9
Other diarrhoeal diseases 623·9 (466·5–814·3) 458·3 (339·1–603·9) –26·5% 11·6 (8·8–14·8) 6·8 (5·0–8·9) –41·6
Typhoid and paratyphoid fevers 136·5 (16·5–254·7) 190·2 (23·8–359·1) 39·4% 2·4 (0·3–4·4) 2·7 (0·3–5·1) 15·5
Lower respiratory infections 3415·4 (3109·5–3650·9) 2814·4 (2487·8–3033·0) –17·6% 62·3 (57·0–67·2) 41·0 (36·3–44·2) –34·1
Infl uenza 574·6 (519·3–625·8) 507·9 (444·2–553·8) –11·6% 10·9 (10·0–11·8) 7·5 (6·5–8·1) –31·8
Pneumococcal pneumonia 858·4 (778·5–932·3) 827·3 (718·4–899·5) –3·6% 17·0 (15·5–18·6) 12·1 (10·5–13·2) –28·7
H infl uenzae type B pneumonia 606·9 (541·5–669·6) 379·9 (337·1–420·5) –37·4% 9·8 (8·9–10·8) 5·5 (4·8–6·0) –44·4
Respiratory syncytial virus pneumonia 534·8 (463·4–608·4) 253·5 (215·0–296·6) –52·6% 7·6 (6·6–8·6) 3·5 (3·0–4·1) –53·3
Other lower respiratory infections 840·6 (747·9–926·9) 845·8 (734·1–927·6) 0·6% 16·9 (15·1–18·6) 12·4 (10·8–13·6) –26·5
Upper respiratory infections 4·0 (3·6–4·2) 3·0 (2·7–3·4) –23·6% 0·1 (0·1–0·1) <0·05 (0·0–0·05) –36·2
Otitis media 5·2 (0·0–61·0) 3·5 (0·0–39·8) –33·5% 0·1 (0·0–1·0) <0·05 (0·0–0·6) –42·3
Meningitis 492·2 (444·1–583·3) 422·9 (360·2–471·7) –14·1% 8·1 (7·4–9·4) 6·1 (5·1–6·7) –25·0
Pneumococcal meningitis 124·9 (111·8–149·3) 118·4 (98·4–132·0) –5·2% 2·1 (1·9–2·5) 1·7 (1·4–1·9) –19·5
H infl uenzae type B meningitis 118·9 (103·2–148·5) 83·0 (70·6–97·0) –30·2% 1·8 (1·5–2·2) 1·2 (1·0–1·4) –33·9
Meningococcal infection 77·1 (68·8–92·7) 75·0 (61·8–85·0) –2·6% 1·3 (1·2–1·5) 1·1 (0·9–1·2) –16·5
Other meningitis 171·3 (153·2–199·2) 146·4 (119·8–164·4) –14·6% 2·9 (2·6–3·3) 2·1 (1·7–2·4) –27·4
Encephalitis 143·5 (126·7–168·1) 119·3 (98·0–137·1) –16·9% 2·4 (2·1–2·8) 1·7 (1·4–2·0) –28·3
Diphtheria 6·3 (0·0–53·0) 2·9 (0·0–24·9) –53·5% 0·1 (0·0–0·8) <0·05 (0·0–0·3) –55·2
Whooping cough 166·5 (0·6–815·7) 81·4 (0·3–399·0) –51·1% 2·3 (0·0–11·4) 1·1 (0·0–5·5) –51·6
Tetanus 272·8 (163·4–456·1) 61·3 (31·0–114·0) –77·5% 4·1 (2·4–7·6) 0·9 (0·4–1·6) –78·8
Measles 631·2 (188·2–1492·6) 125·4 (41·3–295·5) –80·1% 9·0 (2·7–21·3) 1·7 (0·6–4·1) –80·6
Varicella 11·2 (0·0–75·0) 6·8 (0·0–46·4) –38·9% 0·2 (0·0–1·3) 0·1 (0·0–0·7) –50·8
Neglected tropical diseases and malaria 1210·6 (1014·1–1485·4) 1321·8 (1055·6–1677·6) 9·2% 21·0 (17·5–25·9) 18·9 (15·1–23·9) –10·0
Malaria 975·7 (781·2–1239·5) 1169·5 (916·5–1526·9) 19·9% 16·6 (13·4–21·3) 16·7 (13·0–21·7) 0·5
Chagas disease 9·3 (4·6–19·9) 10·3 (5·1–28·6) 10·8% 0·2 (0·1–0·5) 0·2 (0·1–0·4) –30·4
Leishmaniasis 87·2 (50·6–138·4) 51·6 (33·2–76·1) –40·9% 1·5 (0·9–2·4) 0·7 (0·5–1·1) –51·3
African trypanosomiasis 33·5 (9·9–72·7) 9·1 (1·1–29·0) –72·8% 0·6 (0·2–1·4) 0·1 (0·0–0·4) –79·2
Schistosomiasis 10·5 (0·0–62·9) 11·7 (0·0–69·8) 10·9% 0·2 (0·0–1·5) 0·2 (0·0–1·1) –28·6
Cysticercosis 0·7 (0·0–2·8) 1·2 (0·0–4·3) 58·5% <0·05 (0·0–0·1) <0·05 (0·0–0·1) 7·3
Echinococcosis 2·0 (0·0–7·7) 1·2 (0·0–4·7) –41·2% <0·05 (0·0–0·2) <0·05 (0·0–0·1) –62·2
Dengue 11·4 (3·7–23·5) 14·7 (6·1–24·3) 28·9% 0·2 (0·1–0·4) 0·2 (0·1–0·4) 3·2
Rabies 54·1 (32·4–103·4) 26·4 (15·2–45·2) –51·2% 1·0 (0·6–1·9) 0·4 (0·2–0·7) –61·7
(Continues on next page)
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All ages deaths (thousands) Age-standardised death rates (per 100 000)
1990 2010 %Δ 1990 2010 %Δ
(Continued from previous page)
Intestinal nematode infections 3·4 (0·0–16·4) 2·7 (0·0–13·0) –21·7% 0·1 (0·0–0·2) <0·05 (0·0–0·2) –27·3
Ascariasis 3·4 (0·0–16·4) 2·7 (0·0–13·0) –21·7% 0·1 (0·0–0·2) <0·05 (0·0–0·2) –27·3
Other neglected tropical diseases 22·9 (14·3–29·5) 23·7 (16·6–30·9) 3·4% 0·5 (0·3–0·6) 0·3 (0·2–0·5) –23·6
Maternal disorders 358·6 (297·7–429·4) 254·7 (203·8–303·3) –29·0% 6·9 (5·7–8·3) 3·7 (2·9–4·4) –47·2
Maternal haemorrhage 84·8 (69·0–101·7) 58·3 (46·2–68·7) –31·2% 1·7 (1·4–2·0) 0·8 (0·7–1·0) –49·8
Maternal sepsis 33·8 (28·0–41·6) 21·9 (17·6–26·7) –35·3% 0·6 (0·5–0·8) 0·3 (0·2–0·4) –50·8
Hypertensive disorders of pregnancy 69·8 (57·6–85·0) 47·1 (37·7–57·2) –32·5% 1·3 (1·1–1·6) 0·7 (0·5–0·8) –48·8
Obstructed labour 19·1 (15·6–23·8) 10·9 (8·6–13·5) –43·0% 0·4 (0·3–0·5) 0·2 (0·1–0·2) –57·3
Abortion 56·1 (46·4–68·7) 37·1 (29·8–45·1) –33·8% 1·1 (0·9–1·3) 0·5 (0·4–0·6) –50·3
Other maternal disorders 95·1 (78·4–112·8) 79·4 (63·0–92·4) –16·6% 1·9 (1·5–2·2) 1·1 (0·9–1·3) –38·7
Neonatal disorders 3081·1 (2684·2–3393·8) 2236·4 (2014·6–2470·1) –27·4% 42·4 (36·9–46·7) 31·0 (27·9–34·3) –26·8
Preterm birth complications 1204·1 (998·1–1376·8) 859·7 (731·6–990·1) –28·6% 16·6 (13·7–18·9) 11·9 (10·1–13·7) –28·0
Neonatal encephalopathy (birth asphyxia/trauma) 638·1 (516·7–798·1) 511·4 (402·2–619·4) –19·9% 8·8 (7·1–11·0) 7·1 (5·6–8·6) –19·2
Sepsis and other infectious disorders of the newborn baby 534·6 (292·0–817·1) 513·7 (317·6–841·0) –3·9% 7·4 (4·0–11·2) 7·1 (4·4–11·7) –3·1
Other neonatal disorders 704·3 (529·1–860·3) 351·7 (293·5–429·8) –50·1% 9·7 (7·3–11·8) 4·9 (4·1–6·0) –49·7
Nutritional defi ciencies 976·9 (854·4–1155·7) 684·1 (546·0–790·1) –30·0% 17·3 (15·1–20·4) 9·9 (7·9–11·5) –42·8
Protein–energy malnutrition 883·0 (726·7–1052·6) 599·8 (459·4–701·9) –32·1% 15·4 (12·6–18·3) 8·7 (6·6–10·1) –43·7
Iodine defi ciency 2·0 (1·7–2·4) 3·4 (2·4–3·8) 67·7% <0·05 (0·0–0·1) <0·05 (0·0–0·1) 17·5
Iron-defi ciency anaemia 80·8 (66·5–97·8) 69·4 (51·6–78·9) –14·1% 1·6 (1·3–2·0) 1·0 (0·8–1·2) –37·3
Other nutritional defi ciencies 11·1 (9·6–14·0) 11·5 (8·0–12·8) 3·4% 0·2 (0·2–0·3) 0·2 (0·1–0·2) –31·4
Other communicable, maternal, neonatal, and 
nutritional disorders
689·5 (569·9–815·1) 721·2 (626·8–830·4) 4·6% 12·3 (10·4–14·2) 10·6 (9·2–12·1) –14·3
Sexually transmitted diseases excluding HIV 209·4 (130·0–324·3) 118·3 (71·6–187·7) –43·5% 3·0 (1·9–4·6) 1·6 (1·0–2·6) –45·6
Syphilis 202·9 (121·9–315·8) 113·3 (66·9–181·7) –44·1% 2·9 (1·8–4·4) 1·6 (0·9–2·5) –45·4
Sexually transmitted chlamydial diseases 1·5 (0·8–2·0) 1·2 (0·8–1·8) –23·7% <0·05 (0·0–0·05) <0·05 (0·0–0·05) –49·1
Gonococcal infection 1·1 (0·6–1·5) 0·9 (0·6–1·3) –23·6% <0·05 (0·0–0·05) <0·05 (0·0–0·05) –49·0
Other sexually transmitted diseases 3·8 (2·0–5·0) 2·9 (2·0–4·5) –23·6% 0·1 (0·0–0·1) <0·05 (0·0–0·01) –49·0
Hepatitis 210·2 (200·3–221·1) 307·7 (268·2–356·5) 46·4% 4·4 (4·2–4·6) 4·6 (4·0–5·3) 4·6
Acute hepatitis A 99·0 (56·5–154·2) 102·8 (51·2–228·1) 3·9% 2·1 (1·1–3·3) 1·5 (0·8–3·4) –25·1
Acute hepatitis B 68·6 (46·7–84·4) 132·2 (91·1–169·7) 92·7% 1·5 (1·1–1·9) 2·0 (1·4–2·6) 29·2
Acute hepatitis C 8·1 (4·9–11·6) 16·0 (11·6–21·4) 97·1% 0·2 (0·1–0·3) 0·2 (0·2–0·3) 25·6
Acute hepatitis E 34·5 (19·6–55·0) 56·6 (23·3–113·3) 64·2% 0·6 (0·3–0·9) 0·8 (0·3–1·6) 36·1
Other infectious diseases 269·9 (192·2–320·5) 295·2 (205·6–362·1) 9·4% 4·9 (3·5–5·7) 4·3 (3·0–5·3) –11·8
Non-communicable diseases 26 560·3 (25 843·4–27 249·3) 34 539·9 (33 164·7–35 313·0) 30·0% 645·9 (629·9–662·9) 520·4 (499·5–532·0) –19·4
Neoplasms 5779·1 (5415·9–6201·9) 7977·9 (7337·1–8403·8) 38·0% 140·8 (131·9–151·4) 121·4 (111·6–127·9) –13·8
Oesophageal cancer 344·7 (279·7–428·8) 395·2 (298·4–482·1) 14·7% 8·5  (6·9–10·6) 6·1  (4·6–7·4) –28·7
Stomach cancer 774·1 (602·8–1014·2) 754·9 (571·9–990·4) –2·5% 19·0  (14·8–25·0) 11·5 (8·7–15·1) –39·5
Liver cancer 463·0 (386·5–526·8) 752·1 (643·6–880·3) 62·4% 11·2 (9·4–12·8) 11·5 (9·8–13·4) 2·3
Liver cancer secondary to hepatitis B 210·2 (176·9–239·4) 341·4 (290·1–402·6) 62·4% 5·1 (4·3–5·8) 5·2 (4·4–6·1) 2·6
Liver cancer secondary to hepatitis C 113·0 (96·6–129·3) 195·7 (165·2–222·0) 73·3% 2·8 (2·4–3·2) 3·0 (2·5–3·4) 7·6
Liver cancer secondary to alcohol use 93·4 (78·6–106·4) 149·0 (127·3–172·6) 59·5% 2·3 (1·9–2·6) 2·3 (1·9–2·6) –0·1
Other liver cancer 46·5 (38·2–52·6) 66·0 (57·2–77·3) 42·0% 1·1 (0·9–1·2) 1·0 (0·9–1·2) –7·7
Larynx cancer 81·9 (43·5–133·4) 98·3 (52·8–159·2) 20·1% 2·0 (1·1–3·3) 1·5 (0·8–2·4) –25·1
Trachea, bronchus, and lung cancers 1036·3 (825·8–1314·3) 1527·1 (1126·3–1779·4) 47·4% 25·5 (20·4–32·4) 23·4 (17·3–27·3) –8·3
Breast cancer 319·1 (310·1–337·0) 438·7 (420·1–461·9) 37·5% 7·8 (7·6–8·3) 6·6 (6·4–7·0) –15·3
Cervical cancer 192·3 (120·5–264·4) 225·4 (145·2–311·5) 17·3% 4·7 (2·9–6·4) 3·4 (2·2–4·7) –26·9
Uterine cancer 45·2 (25·3–79·4) 58·6 (27·5–87·8) 29·7% 1·1 (0·6–2·0) 0·9 (0·4–1·3) –20·2
Prostate cancer 155·6 (88·8–239·6) 256·0 (141·1–404·4) 64·5% 4·0 (2·3–6·1) 3·8 (2·1–6·1) –3·1
Colon and rectum cancers 490·5 (417·2–547·3) 714·6 (627·9–822·6) 45·7% 12·2 (10·4–13·6) 10·8 (9·5–12·5) –10·9
(Continues on next page)
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Mouth cancer 81·9 (68·6–88·3) 123·9 (104·2–136·3) 51·2% 2·0 (1·7–2·2) 1·9 (1·6–2·1) –5·9
Nasopharynx cancer 45·2 (29·9–59·6) 64·9 (42·3–83·3) 43·6% 1·1 (0·7–1·4) 1·0 (0·6–1·3) –8·2
Cancer of other part of pharynx and oropharynx 74·0 (43·8–90·9) 102·4 (59·5–128·5) 38·3% 1·8 (1·1–2·2) 1·6 (0·9–2·0) –12·9
Gallbladder and biliary tract cancer 97·4 (66·1–136·0) 151·7 (100·4–206·8) 55·7% 2·4 (1·6–3·4) 2·3 (1·5–3·1) –4·7
Pancreatic cancer 200·0 (154·1–261·5) 310·2 (231·7–393·1) 55·1% 5·0 (3·8–6·5) 4·7 (3·5–6·0) –4·8
Malignant melanoma of skin 31·0 (20·3–46·6) 49·1 (29·9–69·5) 58·4% 0·8 (0·5–1·1) 0·7 (0·5–1·1) –1·5
Non-melanoma skin cancer 20·5 (12·5–32·7) 30·6 (17·5–46·3) 49·6% 0·5 (0·3–0·8) 0·5 (0·3–0·7) –10·7
Ovarian cancer 113·6 (82·9–138·8) 160·5 (115·9–200·6) 41·2% 2·8 (2·0–3·4) 2·4 (1·8–3·1) –12·1
Testicular cancer 6·5 (3·8–8·3) 7·7 (4·8–10·0) 18·6% 0·1 (0·1–0·2) 0·1 (0·1–0·1) –18·9
Kidney and other urinary organ cancers 85·1 (62·0–112·9) 162·1 (125·5–219·8) 90·6% 2·1 (1·5–2·7) 2·5 (1·9–3·3) 19·4
Bladder cancer 123·4 (100·2–148·5) 170·7 (131·1–201·2) 38·3% 3·1 (2·5–3·7) 2·6 (2·0–3·0) –16·3
Brain and nervous system cancers 131·5 (88·7–188·3) 195·5 (115·1–239·3) 48·7% 3·0 (2·1–4·4) 3·0 (1·7–3·6) –2·5
Thyroid cancer 24·0 (18·0–29·9) 36·0 (26·4–43·2) 50·2% 0·6 (0·4–0·7) 0·5 (0·4–0·7) –6·7
Hodgkin’s disease 18·9 (11·8–26·2) 17·7 (11·6–25·5) –6·0% 0·4 (0·3–0·6) 0·3 (0·2–0·4) –36·7
Non-Hodgkin lymphoma 143·2 (119·4–158·9) 210·0 (166·0–228·5) 46·7% 3·3 (2·8–3·7) 3·2 (2·5–3·4) –5·0
Multiple myeloma 49·3 (34·5–71·2) 74·1 (48·9–102·2) 50·4% 1·2 (0·9–1·8) 1·1 (0·7–1·6) –7·5
Leukaemia 218·3 (175·7–269·2) 281·3 (219·6–328·0) 28·9% 4·7 (3·8–5·9) 4·2 (3·3–4·9) –11·5
Other neoplasms 412·7 (319·5–521·9) 608·4 (441·2–737·3) 47·4% 9·8 (7·6–12·4) 9·2 (6·7–11·2) –5·7
Cardiovascular and circulatory diseases 11 903·7 (11 329·4–12 589·3) 15 616·1 (14 542·2–16 315·1) 31·2% 298·1 (283·9–314·9) 234·8 (218·7–245·2) –21·2
Rheumatic heart disease 462·6 (431·5–517·7) 345·1 (305·8–374·3) –25·4% 11·1 (10·3–12·4) 5·2 (4·6–5·6) –53·1
Ischaemic heart disease 5211·8 (5014·5–5643·9) 7029·3 (6577·2–7431·1) 34·9% 131·3 (126·4–142·2) 105·7 (98·8–111·9) –19·5
Cerebrovascular disease 4660·4 (4436·1–5154·9) 5874·2 (5304·7–6280·1) 26·0% 105·7 (98·8–111·9) 88·4 (79·8–94·4) –24·6
Ischaemic stroke 2241·1 (2088·0–2494·9) 2835·4 (2657·0–3262·8) 26·5% 57·6 (53·7–64·0) 42·3 (39·6–48·7) –26·6
Haemorrhagic and other non-ischaemic stroke 2419·4 (2050·9–2827·9) 3038·8 (2643·4–3496·9) 25·6% 59·7 (50·6–69·7) 46·1 (40·1–53·1) –22·7
Hypertensive heart disease 590·7 (481·0–740·6) 873·2 (715·5–1074·1) 47·8% 14·9 (12·1–18·6) 13·1 (10·8–16·2) –11·5
Cardiomyopathy and myocarditis 286·8 (250·5–316·8) 403·9 (361·5–450·4) 40·8% 6·7 (5·9–7·4) 6·1 (5·4–6·8) –9·8
Atrial fi brillation and fl utter 34·4 (27·9–43·1) 114·7 (92·7–144·7) 233·9% 0·9 (0·7–1·1) 1·7 (1·4–2·1) 89·6
Aortic aneurysm 131·9 (94·6–173·3) 191·7 (140·3–249·2) 45·3% 3·3 (2·4–4·3) 2·9 (2·1–3·8) –12·7
Peripheral vascular disease 18·6 (12·2–28·7) 49·8 (32·9–74·8) 167·0% 0·5 (0·3–0·7) 0·7 (0·5–1·1) 53·3
Endocarditis 35·8 (30·0–44·4) 48·3 (39·3–55·4) 34·8% 0·8 (0·7–1·0) 0·7 (0·6–0·8) –8·0
Other cardiovascular and circulatory diseases 470·6 (446·3–489·9) 685·9 (664·0–705·3) 45·7% 11·5 (11·0–11·9) 10·3 (9·9–10·5) –10·9
Chronic respiratory diseases 3986·3 (3914·3–4063·8) 3776·3 (3648·2–3934·1) –5·3% 98·2 (96·4–100·1) 57·0 (55·1–59·4) –41·9
Chronic obstructive pulmonary disease 3099·0 (2914·2–3338·6) 2899·9 (2669·3–3245·8) –6·4% 77·4 (72·8–83·3) 43·8 (40·4–49·1) –43·3
Pneumoconiosis 167·0 (86·3–295·2) 124·7 (78·3–196·9) –25·3% 4·2 (2·2–7·3) 1·9 (1·2–3·0) –54·8
Asthma 380·2 (273·8–589·6) 345·7 (282·6–529·1) –9·1% 9·0 (6·6–13·9) 5·2 (4·3–8·0) –42·1
Interstitial lung disease and pulmonary sarcoidosis 65·0 (44·5–89·8) 115·1 (76·7–152·0) 77·2% 1·6 (1·1–2·2) 1·7 (1·2–2·3) 9·1
Other chronic respiratory diseases 275·2 (200·8–375·8) 290·8 (226·8–356·5) 5·7% 6·0 (4·4–8·1) 4·3 (3·4–5·3) –28·3
Cirrhosis of the liver 777·8 (663·1–867·9) 1030·8 (868·8–1160·5) 32·5% 18·6 (15·8–20·7) 15·6 (13·2–17·6) –15·8
Cirrhosis of the liver secondary to hepatitis B 241·7 (198·5–270·5) 312·4 (270·8–378·3) 29·3% 5·8 (4·8–6·5) 4·8 (4·1–5·8) –18·5
Cirrhosis of the liver secondary to hepatitis C 211·9 (181·1–240·7) 287·4 (245·4–330·5) 35·6% 5·2 (4·4–5·9) 4·4 (3·7–5·0) –15·3
Cirrhosis of the liver secondary to alcohol use 206·1 (168·6–245·3) 282·8 (225·6–335·0) 37·2% 5·0 (4·1–5·9) 4·3 (3·4–5·1) –13·9
Other cirrhosis of the liver 118·2 (101·4–136·7) 148·2 (126·6–173·0) 25·4% 2·6 (2·2–3·0) 2·2 (1·9–2·6) –14·4
Digestive diseases (except cirrhosis) 973·1 (877·1–1063·5) 1111·7 (999·5–1210·0) 14·2% 22·9 (20·7–25·0) 16·7 (15·0–18·1) –27·2
Peptic ulcer disease 319·3 (265·9–338·8) 246·3 (215·0–282·2) –22·9% 7·5 (6·3–8·0) 3·7 (3·2–4·2) –50·9
Gastritis and duodenitis 15·6 (11·3–21·1) 14·3 (11·0–18·2) –8·7% 0·4 (0·3–0·5) 0·2 (0·2–0·3) –42·1
Appendicitis 39·5 (27·2–57·0) 34·8 (22·0–46·9) –12·0% 0·8 (0·6–1·2) 0·5 (0·3–0·7) –38·1
Paralytic ileus and intestinal obstruction without hernia 121·0 (78·7–141·1) 148·1 (112·1–192·2) 22·4% 2·8 (1·8–3·2) 2·2 (1·7–2·9) –20·9
Inguinal or femoral hernia 23·3 (22·8–23·7) 17·1 (16·7–17·3) –26·7% 0·5 (0·5–0·6) 0·3 (0·2–0·3) –53·4
Non-infective infl ammatory bowel disease 29·5 (16·8–37·7) 34·0 (23·6–39·7) 15·1% 0·6 (0·4–0·8) 0·5 (0·3–0·6) –20·3
Vascular disorders of intestine 51·4 (28·9–104·6) 73·4 (41·2–150·0) 42·9% 1·3 (0·7–2·6) 1·1 (0·6–2·3) –15·2
(Continues on next page)
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Gallbladder and bile duct disease 74·0 (63·6–93·6) 89·1 (72·1–105·0) 20·4% 1·8 (1·5–2·2) 1·3 (1·1–1·6) –25·5
Pancreatitis 51·6 (37·7–64·6) 76·6 (57·4–95·5) 48·5% 1·2 (0·9–1·5) 1·2 (0·9–1·4) –6·0
Other digestive diseases 247·9 (194·2–296·2) 378·1 (301·6–500·4) 52·5% 5·9 (4·6–7·0) 5·7 (4·5–7·5) –3·1
Neurological disorders 594·5 (468·3–703·0) 1273·8 (980·9–1466·9) 114·3% 13·7 (10·8–16·1) 18·8 (14·5–21·8) 37·8
Alzheimer’s disease and other dementias 141·2 (110·8–208·5) 485·7 (307·8–590·5) 244·0% 3·6 (2·8–5·4) 7·1 (4·5–8·6) 95·4
Parkinson’s disease 53·5 (42·4–70·1) 111·1 (81·2–138·6) 107·7% 1·4 (1·1–1·8) 1·7 (1·2–2·1) 20·8
Epilepsy 130·2 (86·4–167·7) 177·6 (119·7–222·3) 36·4% 2·6 (1·8–3·1) 2·6 (1·7–3·2) 1·0
Multiple sclerosis 15·4 (11·4–18·8) 18·2 (14·1–21·8) 17·8% 0·4 (0·3–0·4) 0·3 (0·2–0·3) –25·0
Other neurological disorders 254·2 (154·1–343·1) 481·1 (317·9–690·7) 89·3% 5·7 (3·5–7·7) 7·2 (4·8–10·4) 25·9
Mental and behavioural disorders 138·1 (95·2–188·0) 231·9 (176·3–329·1) 68·0% 3·2 (2·2–4·3) 3·5 (2·6–4·9) 9·3
Schizophrenia 20·0 (13·1–24·6) 19·8 (16·6–25·0) –1·3% 0·5 (0·3–0·6) 0·3 (0·2–0·4) –36·7
Alcohol use disorders 74·6 (40·1–119·2) 111·1 (64·0–186·3) 48·9% 1·8 (1·0–2·8) 1·7 (1·0–2·8) –5·0
Drug use disorders 26·6 (15·5–56·4) 77·6 (48·8–124·4) 191·7% 0·5 (0·3–1·2) 1·1 (0·7–1·8) 112·5
Opioid use disorders 8·9 (5·0–18·7) 43·0 (26·9–68·4) 385·8% 0·2 (0·1–0·4) 0·6 (0·4–1·0) 257·5
Cocaine use disorders 1·2 (0·7–2·7) 0·5 (0·2–0·5) –55·1% <0·05 (0·0–0·1) <0·05 (0·0–0·05) –67·7
Amphetamine use disorders 0·3 (0·1–0·5) 0·5 (0·1–0·3) 40·1% <0·05 (0·0–0·05) <0·05 (0·0–0·05) 1·5
Other drug use disorders 16·2 (9·6–34·2) 33·6 (21·9–55·9) 107·3% 0·3 (0·2–0·7) 0·5 (0·3–0·8) 50·3
Eating disorders 5·4 (2·4–8·3) 7·3 (4·5–9·9) 35·0% 0·1 (0·1–0·2) 0·1 (0·1–0·1) –12·8
Other mental and behavioural disorders 11·4 (5·2–17·0) 16·1 (9·8–22·1) 41·7% 0·3 (0·1–0·4) 0·2 (0·1–0·3) –11·4
Diabetes, urogenital, blood, and endocrine diseases 1544·3 (1420·0–1804·0) 2726·2 (2447·1–2999·1) 76·5% 36·1 (33·4–41·6) 41·0 (36·8–45·1) 13·8
Diabetes mellitus 665·0 (593·3–757·5) 1281·3 (1065·2–1347·9) 92·7% 16·3 (14·5–18·6) 19·5 (16·2–20·5) 19·7
Acute glomerulonephritis 135·2 (57·4–357·3) 84·2 (41·4–191·8) –37·7% 2·7 (1·2–7·4) 1·2 (0·6–2·8) –54·5
Chronic kidney diseases 403·5 (354·5–468·9) 735·6 (612·1–810·4) 82·3% 9·6 (8·4–11·2) 11·1 (9·2–12·2) 15·4
Chronic kidney disease due to diabetes mellitus 91·9 (79·7–109·9) 178·3 (147·7–198·4) 94·1% 2·3 (2·0–2·7) 2·7 (2·3–3·0) 19·2
Chronic kidney disease due to hypertension 91·5 (80·1–106·9) 175·3 (147·0–193·3) 91·5% 2·2 (2·0–2·6) 2·6 (2·2–2·9) 18·5
Chronic kidney disease unspecifi ed 220·2 (191·9–252·9) 382·0 (317·9–422·3) 73·5% 5·1 (4·5–5·9) 5·7 (4·8–6·3) 12·3
Urinary diseases and male infertility 140·1 (102·5–172·6) 267·1 (204·5–343·4) 90·7% 3·4 (2·5–4·2) 4·0 (3·0–5·1) 18·0
Tubulointerstitial nephritis, pyelonephritis, and urinary 
tract infections
83·0 (61·4–107·2) 163·3 (109·1–199·8) 96·7% 2·0 (1·5–2·6) 2·4 (1·6–3·0) 20·0
Urolithiasis 18·4 (12·4–27·8) 19·0 (11·0–26·0) 3·1% 0·5 (0·3–0·7) 0·3 (0·2–0·4) –36·8
Other urinary diseases 38·6 (26·2–49·3) 84·9 (63·5–114·1) 119·6% 0·9 (0·6–1·1) 1·3 (1·0–1·7) 40·8
Gynaecological diseases 5·1 (3·7–6·4) 7·0 (5·9–8·0) 39·0% 0·1 (0·1–0·1) 0·1 (0·1–0·1) –9·0
Uterine fi broids 0·4 (0·3–0·5) 0·8 (0·6–0·9) 85·7% <0·05 (0·0–0·05) <0·05 (0·0–0·05) 16·5
Endometriosis <0·05 (0·0–0·05) <0·05 (0·0–0·05) 91·5% <0·05 (0·0–0·05) <0·05 (0·0–0·05) 28·6
Genital prolapse 0·2 (0·1–0·2) 0·4 (0·3–0·4) 118·5% <0·05 (0·0–0·05) <0·05 (0·0–0·05) 32·5
Other gynaecological diseases 4·5 (3·2–5·7) 5·9 (4·9–6·7) 31·5% 0·1 (0·1–0·1) 0·1 (0·1–0·1) –13·4
Haemoglobinopathies and haemolytic anaemias 111·4 (72·8–160·4) 114·8 (86·2–151·1) 3·1% 2·1 (1·4–3·0) 1·7 (1·3–2·2) –22·2
Thalassaemias 25·1 (17·0–34·4) 17·9 (15·1–20·4) –28·9% 0·4 (0·3–0·6) 0·3 (0·2–0·3) –41·3
Sickle-cell disorders 23·8 (15·1–32·7) 28·6 (16·8–40·9) 20·5% 0·4 (0·3–0·5) 0·4 (0·2–0·6) 3·6
G6PD defi ciency 4·3 (3·4–5·3) 4·0 (3·5–4·6) –5·6% 0·1 (0·1–0·1) 0·1 (0·1–0·1) –31·8
Other haemoglobinopathies and haemolytic anaemias 58·3 (36·2–91·2) 64·3 (40·9–89·2) 10·3% 1·2 (0·8–1·8) 0·9 (0·6–1·3) –23·0
Other endocrine, nutritional, blood, and immune  disorders 84·0 (42·3–115·5) 236·1 (148·8–417·9) 181·2% 1·8 (0·9–2·5) 3·5 (2·2–6·2) 91·8
Musculoskeletal disorders 69·5 (46·2–89·6) 153·5 (110·7–214·8) 121·0% 1·7 (1·1–2·2) 2·3 (1·7–3·2) 37·8
Rheumatoid arthritis 33·5 (23·5–43·5) 48·9 (37·9–68·6) 45·8% 0·8 (0·6–1·1) 0·7 (0·6–1·0) –9·9
Other musculoskeletal disorders 36·0 (25·0–42·8) 104·7 (83·8–143·7) 191·0% 0·8 (0·6–1·0) 1·6 (1·2–2·1) 84·0
Other non-communicable diseases 793·9 (670·6–970·4) 641·7 (524·8–721·4) –19·2% 12·7 (10·8–15·3) 9·2 (7·5–10·3) –28·0
Congenital anomalies 663·2 (551·7–843·4) 510·4 (404·7–596·3) –23·0% 10·1 (8·4–12·7) 7·2 (5·7–8·4) –28·3
Neural tube defects 118·5 (70·5–173·3) 70·8 (39·8–104·6) –40·3% 1·7 (1·0–2·5) 1·0 (0·6–1·5) –42·2
Congenital heart anomalies 278·9 (234·9–355·9) 223·6 (199·5–246·7) –19·8% 4·3 (3·7–5·3) 3·2 (2·8–3·5) –26·4
Cleft lip and cleft palate 8·4 (3·3–16·6) 3·7 (2·1–5·5) –56·2% 0·1 (0·0–0·2) 0·1 (0·0–0·1) –56·2
(Continues on next page)
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Decomposition of changes in numbers of causes of 
death into demographic and epidemiological factors
To help understand the drivers of change in the numbers 
of deaths by cause or region, we decomposed change 
from 1990 to 2010 into growth in total population, change 
in population age and sex structure, and change in 
age-specifi c and sex-specifi c rates. We computed two 
counterfactual sets of cause of death numbers: (1) a 
population growth scenario computed as the number of 
deaths expected in 2010 if only total population numbers 
increased to the level of 2010 but the age-sex structure of 
population stayed the same as in 1990 and age-sex 
All ages deaths (thousands) Age-standardised death rates (per 100 000)
1990 2010 %Δ 1990 2010 %Δ
(Continued from previous page)
Down’s syndrome 22·0 (9·8–37·5) 17·4 (11·1–25·4) –21·0% 0·3 (0·2–0·6) 0·2 (0·2–0·4) –28·3
Other chromosomal abnormalities 34·6 (11·9–80·3) 18·9 (9·7–33·8) –45·4% 0·5 (0·2–1·1) 0·3 (0·1–0·5) –46·8
Other congenital anomalies 200·8 (115·8–298·9) 176·0 (118·9–218·7) –12·3% 3·1 (1·9–4·5) 2·5 (1·7–3·1) –19·3
Skin and subcutaneous diseases 100·6 (77·5–118·3) 109·2 (84·9–124·0) 8·5% 2·2 (1·7–2·6) 1·6 (1·3–1·8) –26·5
Cellulitis 26·1 (19·9–30·8) 26·6 (20·4–30·2) 2·0% 0·6 (0·4–0·7) 0·4 (0·3–0·5) –28·9
Abscess, impetigo, and other bacterial skin diseases 42·1 (31·2–51·0) 39·7 (31·1–45·1) –5·7% 0·8 (0·6–1·0) 0·6 (0·5–0·7) –30·6
Decubitus ulcer 32·1 (26·0–38·5) 42·6 (32·9–48·7) 32·5% 0·8 (0·6–1·0) 0·6 (0·5–0·7) –20·6
Other skin and subcutaneous diseases 0·3 (0·1–0·1) 0·4 (0·1–0·1) 4·4% <0·05 (0·0–0·05) <0·05 (0·0–0·05) –28·7
Sudden infant death syndrome 30·0 (15·4–56·7) 22·0 (13·1–36·5) –26·7% 0·4 (0·2–0·8) 0·3 (0·2–0·5) –26·7
Injuries 4091·7 (3851·9–4489·7) 5073·3 (4556·7–5548·1) 24·0% 82·0 (77·2–90·3) 74·3 (66·8–81·3) –9·3
Transport injuries 958·2 (770·4–1175·0) 1396·8 (1101·4–1850·1) 45·8% 19·4 (15·4–23·6) 20·5 (16·1–27·1) 5·9
Road injury 907·9 (764·1–1123·4) 1328·5 (1050·9–1747·0) 46·3% 18·4 (15·4–22·7) 19·5 (15·4–25·6) 6·2
Pedestrian injury by road vehicle 284·1 (210·6–333·9) 461·0 (337·1–617·3) 62·3% 5·8 (4·2–6·7) 6·8 (5·0–9·1) 17·6
Pedal cycle vehicle 54·9 (41·7–66·7) 83·3 (62·3–101·4) 51·7% 1·1 (0·9–1·4) 1·2 (0·9–1·5) 7·8
Motorised vehicle with two wheels 131·7 (99·4–163·4) 206·4 (159·7–233·8) 56·7% 2·6 (2·0–3·3) 3·0 (2·3–3·4) 14·4
Motorised vehicle with three or more wheels 336·9 (268·8–420·5) 474·5 (379·3–581·4) 40·9% 6·8 (5·5–8·4) 7·0 (5·6–8·5) 2·4
Road injury other 100·3 (49·0–182·3) 103·3 (50·7–202·2) 3·0% 2·0 (1·0–3·7) 1·5 (0·7–3·0) –25·2
Other transport injury 50·2 (41·7–65·1) 68·3 (58·0–82·7) 35·9% 1·0 (0·8–1·3) 1·0 (0·8–1·2) –0·0
Unintentional injuries other than transport injuries 2030·1 (1896·0–2266·8) 2122·8 (1867·5–2283·8) 4·6% 39·6 (37·1–44·3) 31·0 (27·3–33·4) –21·6
Falls 348·6 (311·2–415·3) 540·5 (415·2–611·9) 55·0% 7·8 (7·0–9·4) 8·0 (6·1–9·1) 2·0
Drowning 432·9 (353·3–516·1) 349·1 (299·9–437·8) –19·4% 7·5 (6·3–9·0) 5·1 (4·3–6·3) –33·1
Fire, heat, and hot substances 280·1 (233·6–330·1) 337·6 (234·7–433·8) 20·5% 5·3 (4·5–6·3) 4·9 (3·4–6·3) –7·3
Poisonings 202·9 (157·3–326·8) 180·4 (130·1–239·9) –11·1% 4·0 (3·2–6·5) 2·6 (1·9–3·5) –34·4
Exposure to mechanical forces 276·0 (199·6–417·1) 215·6 (154·6–255·3) –21·9% 5·5 (4·0–8·1) 3·2 (2·3–3·7) –42·2
Mechanical forces (fi rearm) 127·5 (76·8–206·0) 79·8 (52·0–127·1) –37·4% 2·5 (1·5–4·1) 1·2 (0·8–1·8) –53·2
Mechanical forces (other) 148·5 (103·0–197·4) 135·7 (83·5–161·0) –8·6% 3·0 (2·1–3·9) 2·0 (1·2–2·4) –33·1
Adverse eff ects of medical treatment 42·0 (32·7–49·3) 83·7 (64·6–96·2) 99·1% 0·9 (0·7–1·0) 1·2 (1·0–1·4) 41·0
Animal contact 75·0 (50·7–97·5) 64·3 (41·0–88·4) –14·3% 1·4 (1·0–1·9) 0·9 (0·6–1·3) –34·4
Animal contact (venomous) 54·9 (30·1–89·3) 47·0 (25·6–84·7) –14·3% 1·0 (0·6–1·7) 0·7 (0·4–1·2) –34·4
Animal contact (non-venomous) 20·1 (10·7–30·8) 17·3 (10·0–24·6) –14·2% 0·4 (0·2–0·6) 0·3 (0·1–0·4) –34·5
Unintentional injuries not classifi ed elsewhere 372·5 (311·9–403·8) 351·6 (301·4–387·8) –5·6% 7·1 (6·0–7·7) 5·1 (4·4–5·7) –27·9
Self-harm and interpersonal violence 1008·5 (838·8–1201·9) 1340·0 (1108·2–1616·9) 32·9% 21·1 (17·5–25·4) 19·7 (16·2–23·8) –6·9
Self-harm 669·8 (519·5–853·4) 883·7 (655·6–1105·2) 31·9% 14·5 (11·3–18·4) 13·1 (9·7–16·3) –9·6
Interpersonal violence 338·7 (245·8–416·6) 456·3 (354·9–610·9) 34·7% 6·7 (4·8–8·3) 6·6 (5·1–8·9) –1·0
Assault by fi rearm 141·8 (107·4–175·7) 196·2 (153·9–233·6) 38·4% 2·8 (2·1–3·5) 2·8 (2·2–3·4) 1·9
Assault by sharp object 83·1 (55·4–119·8) 126·7 (82·2–188·2) 52·5% 1·7 (1·1–2·4) 1·8 (1·2–2·7) 10·9
Assault by other means 113·8 (85·2–129·3) 133·4 (107·3–159·0) 17·2% 2·2 (1·7–2·5) 1·9 (1·6–2·3) –13·5
Forces of nature, war, and legal intervention 94·9 (65·0–162·3) 213·7 (119·2–433·5) 125·2% 1·9 (1·3–3·4) 3·1 (1·7–6·3) 62·0
Exposure to forces of nature 31·4 (18·2–60·0) 196·0 (106·9–401·9) 523·5% 0·7 (0·4–1·3) 2·9 (1·6–5·8) 336·4
Collective violence and legal intervention 63·5 (44·3–101·8) 17·7 (12·2–29·6) –72·2% 1·3 (0·9–2·1) 0·3 (0·2–0·4) –79·5
Data are deaths (95% uncertainty interval) or % change. %Δ=percentage change. E coli=Escherichia coli. H infl uenzae=Haemophilus infl uenzae. G6PD=glucose-6-phosphate dehydrogenase. *For these causes the 
mean value is outside of the 95% uncertainty interval; this occurs because the full distribution of 1000 draws is asymmetric with a long tail. A small number of high values in the uncertainty distribution raises the 
mean above the 97·5 percentile of the distribution. 
Table 2: Global deaths for 235 causes in 1990 and 2010 for all ages and both sexes combined (thousands) and age-standardised rates (per 100 000) with 95% UI and percentage change
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specifi c rates remained at 1990 levels; and, (2) a 
population growth and population ageing scenario 
computed as the number of deaths expected in 2010, 
using 1990 age-sex specifi c rates and 2010 age-specifi c 
and sex-specifi c population numbers. The diff erence 
between 1990 num bers and the population growth 
scenario is the change in death numbers due strictly to 
the growth in total population. The change from the 
population growth scenario to the population growth and 
ageing scenario is the number of deaths due to ageing of 
the population. The diff erence between 2010 deaths and 
the population growth and ageing scenario is the 
diff erence in death numbers due to epidemiological 
change in age-specifi c and sex-specifi c death rates. Each 
of these three diff erences is also presented as a percentage 
change with reference to the 1990 death number.
We calculated change in the risk of death, by cause, 
directly using age standardised death rates, based on the 
WHO world population standard age structure.62 Further 
details on the data and methods used for specifi c causes 
of death are available on request.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all of the data in the study and the fi nal 
responsibility to submit for publication.
Results
The GBD 2010 cause list divides causes into three broad 
groups. At the most aggregate level, communicable, 
maternal, neonatal, and nutritional causes account for 
13·2 million (24·9%) of 52·8 million total deaths at all ages 
in 2010. Non-communicable causes account for 34·5 mil-
lion or 65·5%. The third category, injuries, accounts for 
5·1 million or 9·6%. The continued decrease in deaths 
from communicable, maternal, neonatal, and nutritional 
disorders is striking, if not surprising. The number of 
deaths from these disorders decreased by 2·7 million from 
15·9 million in 1990 to 13·2 million in 2010, representing a 
17% decrease from 1990 to 2010. The annual number of 
deaths from non-com municable diseases, by contrast, rose 
by just under 8 million, to 34·5 million, or two of every 
three deaths in 2010. The global fraction of deaths due to 
injuries in creased slightly between 1990 and 2010 (from 
8·8% to 9·6%), but this masks some important trends in 
mortality from these causes. 
Table 1 decomposes these global trends into the 
contribution of total increase in population size, ageing of 
the population, and changes in age-specifi c and sex-
specifi c rates. Global population growth alone would have 
been expected to increase deaths from all causes by 31·8% 
from 1990 to 2010. Because of the correlation between 
population growth rates and mortality rates from com-
municable, maternal, neonatal, and nutritional causes, 
population growth alone would have increased this 
category by 46·9%, non-communicable diseases by 22·9%, 
and injuries by 31·1% (table 1). Ageing of the world’s popu-
lation such that the mean age of the world increased from 
26·1 years to 29·5 years contributed to an 11·2% decrease 
in communicable, maternal, neo natal, and nutritional 
disorders, a 39·2% increase in non-com municable disease 
deaths, and a 9·2% increase in injuries (table 1). Declines 
in age-specifi c and sex-specifi c death rates have contributed 
to a 52·7% decrease in communicable, maternal, neonatal, 
and nutritional deaths, a 32·1% de crease in non-com-
municable disease deaths, and a 16·3% decrease in injury 
deaths. With decreasing age-specifi c death rates from all 
three groups of causes, including non-communicable 
diseases, the global shift towards non-communicable 
diseases and injuries as leading causes of death is being 
driven by population growth and ageing, and not by 
increases in age-sex-cause specifi c death rates.
At the second level of the GBD 2010 cause hierarchy, 
there are 21 major cause groups. Figure 1 (A–D) sum-
marises the composition of causes of death for every age-
sex group for male and female individuals separately in 
1990 and 2010 at this second level of cause disaggregation. 
The structure of causes of death changed systematically 
with age. In the neonatal age groups, disorders arising 
during the neonatal period dominated, but with im portant 
contributions from the category of diarrhoeal disease, 
lower respiratory infections, and other infectious and non-
communicable diseases, including congenital causes. By 
the post-neonatal period, causes of death were dominated 
by diarrhoea, lower respiratory infections, and other 
infectious diseases such as measles, among others. At ages 
1–4 years, the category neglected tropical diseases and 
malaria were also an important contributor to global 
mortality. In the age group 5–14 years, infectious diseases, 
HIV/tuberculosis (HIV/TB), injuries, and some cancers 
predominated, although overall mortality at these ages was 
low. Important sex diff erences were evident from ages 
15–34 years; among male individuals, injuries, HIV/TB, 
and some non-communicable diseases predominate. 
Among female individuals of the same age group, injuries 
were a smaller cause of death with maternal causes making 
an important contribution. In 2010, maternal causes 
accounted for 10·7% of deaths of women in this age group. 
By age 40 years, more than 50% of global deaths in 
1990 were from non-communicable diseases—this tran-
sition age shifts to 45 years in 2010 because of the HIV 
epidemic. Beginning at age 50 years, circulatory causes 
begin a steady rise to become the largest cause of death.
The comparison of the 1990 and 2010 plots shows various 
shifts in the cause structure by age and sex (fi gure 1). At 
younger age groups, neonatal disorders and other non-
communicable causes, including con genital anomalies, 
predominate. The unfolding HIV/AIDS epidemic at the 
global level is clearly evident from the huge increase in the 
contribution of HIV/TB to cause of death patterns among 
young adult men and women. By 2010, for example, 
HIV/TB and injuries accounted for more than half of all 
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deaths in the age group 20–39 years in men. Other 
important shifts, with age, are evident—namely, a rising 
fraction of deaths in many age groups from diabetes, 
chronic kidney diseases, blood and endocrine disorders, 
and cancers, along with a decrease in the fraction due to 
chronic respiratory deaths in the middle-aged and older 
groups. For women, the share of deaths at ages 20–39 years 
due to maternal causes notably decreased.
At a more disaggregated cause level, there is interest in a 
broad global overview of who dies of what, and how this is 
Figure 2: Pie chart of global neonatal, post-neonatal, and child deaths in 2010 for children of both sexes combined by cause
(A) Age 0–27 days (neonatal); 2 840 157 total deaths. (B) Age 28–364 days (post-neonatal); 2 031 474 total deaths. (C) Age 1–4 years; 1 969 567 total deaths. ETEC=enterotoxigenic Escherichia coli. 
EPEC=enteropathogenic E coli. Hib=Haemophilus infl uenzae type B. RSV=respiratory syncytial virus. 
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changing. Table 2 provides total numbers of deaths and 
age-standardised death rates for each cause in 1990 and 
2010. Because there is substantial interest in causes of 
death for diff erent age groups, we provide global deaths 
for the 20 GBD age groups, by sex, and including 95% UI 
for 2010 and 1990 (appendix pp 149–340). In addition to 
the numbers of deaths, we present the death rates by age 
for 2010 and 1990 in for those readers interested in com-
paring change in age-sex-specifi c death rates (appendix 
pp 341–533). There are many features of the tables that 
warrant discussion: we limit ourselves here to some 
general observations that we believe characterise the 
principal epidemiological trends around the turn of the 
millennium. Much of the de crease in the communicable, 
maternal, neonatal, and nutritional causes was due to the 
substantial reductions in diarrhoeal disease (from 2·5 to 
1·4 million), lower respiratory infections (from 3·4 to 
2·8 million), neonatal disorders (from 3·1 to 2·2 million), 
measles (from 0·63 to 0·13 million), and tetanus (from 
0·27 to 0·06 million), refl ecting the scaling up of eff ective 
treatments and technologies to combat these disorders 
generally associated with poverty (table 2). Not all dis eases 
in this category decreased, however. Table 2 shows the 
massive increase in deaths between 1990 and 2010 from 
HIV/AIDS (from 0·3 to 1·5 million), despite the decrease 
after 2006, as well as a 19·9% rise in malaria mortality 
over the two decades.
Cancers claimed 8·0 million lives in 2010, 15·1% of all 
deaths worldwide, with large increases in deaths from 
trachea, bronchus, and lung cancers, twice the number of 
deaths from the next two most common sites for mortality 
(liver and stomach). Roughly half of the total liver cancer 
mortality was attributed to hepatitis B infection, with 
smaller fractions due to hepatitis C and alcohol (table 2). 
The largest cause fraction (13·3%) among all causes of 
death in 2010 was due to ischaemic heart disease, closely 
followed by stroke (11·1%), being roughly split equally 
between ischaemic stroke and haemorrhagic and other 
non-ischaemic stroke (table 2). Together, ischaemic heart 
disease and all forms of stroke killed an estimated 
12·9 million people in 2010, a quarter of the global total, 
compared with one in fi ve deaths worldwide 20 years 
earlier. Cirrhosis of the liver was the cause of a million 
deaths in 2010, 33% more than in 1990, roughly equally 
attributable to hepatitis B, hepatitis C, and alcohol. 
Diabetes deaths worldwide almost doubled, as did deaths 
from chronic kidney disease. Deaths from Alzheimer’s 
disease and other dementias rose more than three-fold, 
and deaths from Parkinson’s disease doubled. One of the 
few causes in this group to decrease was COPD, falling 
from 3·1 to 2·9 million. This is consistent with the 
decreases observed with development in countries such 
as the UK in the fi rst part of the 20th century, only to be 
reversed as the eff ect of tobacco use becomes evident.63,64 
Figure 3: Global deaths in 2010 for individuals aged 15–49 years
(A) Female individuals, 3 496 480 total deaths. (B) Male individuals, 5 741 344 total deaths. CKD=chronic kidney disease.
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The mas sive increases in tobacco use since the 1970s, 
especially in men in less developed countries, might 
reverse this trend over the next decade or so.65
One million more deaths from injuries occurred in 
2010 (5·1 million) than two decades earlier, a 24% 
increase (table 2). This was driven primarily by a 
420 600 increase in road traffi  c deaths, which claimed 
1·3 million lives in 2010. Falls also claimed an additional 
191 900 lives compared with 1990, with most other 
ac ci dental causes being relatively constant, or decreasing, 
especially drowning. Deaths from intentional injuries 
increased for both self-harm and interpersonal violence. 
Deaths from forces of nature, war, and legal intervention 
were more than twice as common than two decades 
earlier. Given the huge annual fl uctuation in deaths from 
forces of nature and war, trends must be interpreted with 
caution. The fact that deaths from injuries are rising, and 
account for one in ten deaths worldwide, argues for far 
greater policy action to prevent them.
Trends in numbers of deaths are of interest and impor-
tance for health services and health policies that are 
designed to reduce premature mortality from various 
causes. Yet numbers of deaths alone do not provide a clear 
indication of whether disease control strategies are 
working since they are heavily dependent on changes in 
population size and age structure. By computing age-
standardised mortality rates, we eff ectively controlled for 
demographic changes across populations over time; 
however, age-standardised death rates are sensitive to the 
population standard used. Changes in age-standardised 
mortality rates between 1990 and 2010 are shown in the 
right hand panels of table 2. Death rates from all 
communicable, maternal, neonatal, and nutritional dis-
orders have decreased by 30% since 1990, a much greater 
reduction than sug gested from numbers of deaths alone 
(table 2). The age-standardised death rate from diarrhoeal 
diseases fell by 49%, whereas lower respira tory infections 
decreased by 34%. Interestingly, age-standardised death 
rates from trachea, bronchus, and lung cancers fell by 8% 
between 1990 and 2010, despite a 47% increase in numbers 
of deaths, due to continued decreases in mortality in 
developed countries and more modest increases in less 
developed countries where the full impact of smoking, 
especially in men, has yet to occur. Breast cancer mortality 
Figure 4: Global death ranks with 95% UIs for the top 25 causes in 1990 and 2010, and the percentage change with 95% UIs between 1990 and 2010
UI=uncertainty interval. COPD=chronic obstructive pulmonary disease. *Includes birth asphyxia/trauma. An interactive version of this fi gure is available online at 
http://healthmetricsandevaluation.org/gbd/visualizations/regional.
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33 Rheumatic heart disease
18·3 (14 to 22) 18 Hypertensive heart disease
10·4 (8 to 14) 10 Road injury
16·9 (13 to 20) 17 Neonatal encephalopathy*
23·7 (20 to 28) 24 Liver cancer
9·4 (7 to 13) 9 Malaria
3·0 (3 to 4) 3 Lower respiratory infections
12·8 (11 to 16) 12 Cirrhosis
21·1 (6 to 44) 19 Measles
5·0 (5 to 5) 5 Diarrhoea
8·6 (7 to 12) 8 Lung cancer
9 Diabetes 93 (68 to 102)
23 Congenital anomalies –22 (–40 to –3)
17 Stomach cancer –2 (–10 to 5)
14 Hypertensive heart disease 48 (39 to 56)
4 Lower respiratory infections –18 (–24 to –11)
19 Colorectal cancer 46 (36 to 63)
5 Lung cancer 48 (24 to 61)
30 Falls
1 Ischaemic heart disease 35 (29 to 39)
15 Preterm birth complications –28 (-39 to -17)
 2 Stroke 26 (14 to 32)
6 HIV/AIDS 396 (323 to 465)
22 Falls 56 (20 to 84)
11 Malaria 21 (–9 to 56)
7 Diarrhoea –42 (–49 to –35)
25 Neonatal sepsis –3 (–25 to 27)
12 Cirrhosis 33 (25 to 41)
16 Liver cancer 63 (49 to 78)
21 Protein–energy malnutrition –32 (–42 to –21)
24 Neonatal encephalopathy* –20 (–33 to –2)
27 Chronic kidney disease
46 (40 to 55)
8 Road injury 47 (18 to 86)
10 Tuberculosis –18 (–35 to –3)
18 Chronic kidney disease 82 (65 to 95)
3 COPD –7 (–12 to 0)
13 Self-harm 32 (8 to 49)
62 Measles35 HIV/AIDS
9·0 (7 to 11)
24·4 (21 to 29)
17·0 (13 to 22)
14·2 (12 to 18)
3·6 (3 to 4)
18·5 (15 to 21)
5·8 (5 to 10)
1·0 (1 to 1)
14·4 (12 to 18)
2·0 (2 to 2)
6·4 (5 to 8)
23·3 (21 to 29)
10·3 (6 to 13)
6·7 (5 to 9)
25·1 (15 to 35)
11·8 (10 to 14)
16·9 (14 to 20)
21·5 (19 to 25)
24·4 (21 to 30)
19·7 (18 to 21)
8·4 (5 to 11)
10·1 (8 to 13)
17·4 (15 to 21)
3·4 (3 to 4)
14·1 (11 to 20)
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rates fell by 15%, even though numbers of deaths from the 
disease increased by more than a third.
Our fi ndings suggest important decreases (20% or 
more) in age-standardised death rates from major vascular 
diseases, especially heart disease and strokes, for the 
world as whole, even though numbers of vascular disease 
deaths increased by a third to 15·6 million in 2010 (table 2). 
Death rates for COPD and liver cirrhosis also decreased, 
but almost doubled for Alzheimer’s disease, and rose for 
diabetes and chronic kidney disease. These represent 
important global health challenges that might, or might 
not, be evident from an assessment of trends in numbers 
of deaths alone. Globally, although the number of deaths 
from injury rose by 24% since 1990, death rates decreased 
modestly, although this masks variable trends for diff erent 
injuries, with death rates from drownings and poisonings 
falling by about a third, less dramatically for self-harm and 
violence, and rising for transport injuries and, interest-
ingly, from adverse eff ects of medical treatment. Death 
rates from forces of nature also massively increased (by 
336%) comparing 1990 to 2010 because of the earthquake 
in Haiti in 2010.
Causes of death in children younger than 5 years are 
of particular interest because of the global focus on 
improving child survival over the past few decades that has 
been reinforced by the push to achieve Millennium 
Development Goal (MDG) 4 (to reduce by two thirds, 
between 1990 and 2015, the under-5 mortality rate) in 
recent years. The appendix (pp 149–340) provides a 
breakdown of deaths in children younger than 5 years into 
the early neonatal, late neonatal, post-neonatal, and 
1–4 years age groups in 2010 and 1990. To facilitate an 
understanding of the leading causes at diff erent ages 
under 5 years, we show in fi gure 2A, B, and C the 
distribution of deaths in the neonatal periods, the post-
neonatal period, and ages 1–4 years, respectively. Of 
2·8 million early and late neonatal deaths, we estimate that 
2·1 million were from neonatal disorders including 
preterm birth compli cations, neonatal sepsis, and neonatal 
encephalopathy, among others. A further 137 000 deaths 
were also due to disorders that arise in the neonatal period 
but which lead to death after the fi rst month of life. 
Among the important neonatal disorders, preterm events 
accounted for 29% of global neonatal deaths, with nearly 
equal shares for neonatal sepsis and neonatal encephal-
opathy—17% each. Of the remaining 741 000 neonatal 
deaths, congenital anomalies accounted for 183 000 deaths, 
although most congenital deaths occured after the 
fi rst month of life. Injuries accounted for 28 000 neo-
natal deaths; other non-communicable causes including 
haemoglobinopathies and haemolytic anaemias, some 
rare cancers, sudden infant death syndrome (SIDS), and 
other rare causes accounted for 45 000 deaths. Among 
communicable diseases, notably lower respiratory infec-
tions (194 000), diarrhoea (77 000), and meningitis (46 000) 
accounted for the remaining neonatal deaths.
In the post-neonatal period (fi gure 2B), we estimated 
2·0 million deaths. Nearly half of these deaths were due to 
three diseases: lower respiratory infections, diar rhoeal 
diseases, and malaria. Other important causes of death 
during the post-neonatal period included nutri tional 
defi ciencies, meningitis and encephalitis, injuries, 
whooping cough, measles, and HIV/AIDS. Causes that 
primarily lead to death in the neonatal period also 
contributed to 14·0% of deaths between 1 month and 
11 months including neonatal disorders, congenital 
anomalies, and congenital syphilis. Our analysis of lower 
respiratory infections disaggregated by pathogen suggested 
that the most important identifi ed causes of post-neonatal 
lower respiratory infections were respiratory syncytial 
virus (RSV), Haemophilus infl uenzae type B (Hib), and 
pneumococcus. For diar rhoeal diseases, the most import-
ant pathogen was rotavirus followed by crypto sporidium. 
In the age group 1–4 years (fi gure 2C), we noted 2·0 million 
deaths distributed across a wider array of causes. The most 
important cause globally in this age group was malaria, 
followed by lower respiratory infec tions, diarrhoeal 
diseases, and nutritional defi ciencies. These four causes 
accounted for 52·4% of deaths in this age group. Four 
causes account for between 3% and 5% of deaths each: 
HIV/AIDS, meningitis or encephalitis, measles, and 
drowning. The specifi c pathogens causing lower 
respiratory infections substantially shifted in this age 
group compared with the age groups of under 1 year with a 
much more substantial part played by pneumococcal 
deaths. Just under 14% of deaths in this age group were 
from a long list of non-communicable causes, each of 
which accounted for a relatively small number of deaths.
Figure 5: Percentage of global years of life lost (YLLs) from 1990 to 2010 for all ages and both sexes combined 
by cause and year
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Because of the focus of MDG 5 on maternal mortality, 
the composition of causes of death in women and men of 
reproductive age is of particular interest. Although deaths 
related to pregnancy and childbirth have been given special 
priority in the MDGs, any death in these young adult age 
groups is a major cause for concern. For women aged 
15–49 years, we estimated 3·5 million deaths from all 
causes in 2010. Figure 3A shows that the leading cause was 
HIV/AIDS, followed by cardio vascular disease, maternal 
disorders, suicide, tuber culosis, breast and cervical cancer, 
and digestive diseases and cirrhosis. The top seven causes 
accounted for half of the deaths of women in these age 
groups. Although there is no MDG related specifi cally to 
male deaths in the reproductive age groups, disorders 
targeted by MDG 6 take an important toll on men in the 
age groups 15–49 years. The leading causes of death for 
men in this age group, however, were cardiovascular 
diseases, road traffi  c injuries, and HIV/AIDS, with other 
major causes including suicide and interpersonal violence.
Identifi cation of more detailed causes is perhaps 
more important for priority setting and planning, since 
interventions are generally cause-specifi c. Figure 4 shows 
the top 25 causes of death in the world ranked in 1990 and 
2010 with arrows connecting the causes be tween the two 
periods. Although the top four causes of death in 
1990 remain the top four in 2010, the change in numbers 
of deaths is noteworthy, with ischaemic heart disease and 
stroke increasing by 26–35% over the interval, but lower 
respiratory infections and COPD declining by 7–18%. 
Lung cancer increased from the 8th cause to the 5th cause 
in the two decades because of a 48% increase in absolute 
number of deaths. The largest change was for HIV/AIDS, 
rising from the 35th cause to the 6th leading cause of 
death. Diarrhoea, tuberculosis, and malaria all dropped 
in the global league table. Large increases in absolute 
number of deaths and their relative importance can be 
seen for diabetes, liver cancer, falls, and chronic kidney 
disease. Each of these causes has increased by more than 
50% over the two decades.
Whereas the number of deaths from a given cause is a 
widely understood measure, its utility as a metric for 
informing public health priorities is limited since it gives 
Figure 6: Global years of life lost (YLLs) ranks with 95% UIs for the top 25 causes in 1990 and 2010, and the percentage change with 95% UIs between 1990 
and 2010
YLLs=years of life lost. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease. *Includes birth asphyxia/trauma. An interactive version of this fi gure is 
available online at http://healthmetricsandevaluation.org/gbd/visualizations/regional. 
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equal weight to a death at age 90 years compared, for 
example, with a death at age 25 years or 5 years. 
Consequently, the predominance of non-communicable 
causes might be misleading. In the Global Burden of 
Disease studies, the computation of years of life lost based 
on the standard expectation of life at the age of each death 
quantifi ed the amount of life lost due to premature 
mortality (YLLs) from each cause. By computing YLLs, we 
could aggregate information on deaths across all ages to 
summarise overall patterns of premature mortality. 
Figure 5 shows the demographic and epidemiological 
transition, with the change in the composition of YLLs by 
single year from 1990 to 2010 for both sexes combined. 
The eff ect of major mortality shocks such as the Rwanda 
genocide (1994) and the famine in North Korea (covering 
most of the 1990s with a peak in 1995), were evident even 
at the global scale. The fraction of YLLs due to diarrhoea, 
lower respiratory infections, meningitis, and other com-
mon infectious diseases decreased substantially from 
27·3% in 1990 to 15·4% in 2010. The percentage due to 
HIV/TB has increased due to the HIV epidemic. There is 
a concomitant expansion of YLLs due to non-com-
municable diseases, particularly cardiovascular diseases. 
The share of YLLs from non-communicable diseases 
increased from 33·3% in 1990 to 42·8% in 2010. The 
appendix (pp 534–725) shows the global YLLs with 
95% UIs for 2010 and 1990.
Figure 6 provides a comparison of the top 25 causes of 
YLLs for both sexes combined, which gives an even more 
meaningful perspective on priorities for disease control 
than a simple ranking of causes of death according to the 
numbers of deaths from each cause. The leading cause of 
YLLs globally was lower respiratory infections in 1990 and 
ischaemic heart disease in 2010; in this period, the total 
number of YLLs from lower respiratory infections 
decreased by 45% but increased 28% for ischaemic heart 
disease. More generally, a number of communicable, 
maternal, neonatal, and nutritional causes declined in 
both absolute terms and in relative importance as 
causes of YLLs—most notably measles, tetanus, preterm 
birth complications, tuberculosis, meningitis, and 
protein-energy malnutrition. Conversely, several non-
communicable diseases increased in im portance over the 
two decades: ischaemic heart disease, stroke, lung cancer, 
cirrhosis, diabetes, liver cancer, and chronic kidney 
disease particularly, although COPD and congenital 
causes have declined in rankings of YLLs. Among 
injuries, road traffi  c, self-harm, and interpersonal vio-
lence increased substantially in both absolute and relative 
terms, whereas drowning decreased.
An important innovation in this study was the 
quantifi cation of uncertainty by cause. UIs varied widely 
across causes. Figure 7 shows the 95% UIs for YLLs for 
each cause in 2010, ordered by the mean rank of every 
cause. The two leading causes—ischaemic heart disease 
and lower respiratory infections—have nearly overlapping 
UIs. These two causes are separated by a substantial gap 
with the next highest ranked cause, stroke. The 12th ranked 
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Figure 7: Global YLLs (millions) with 95 % uncertainty intervals versus rank by cause in 2010
YLLs=years of life lost. An interactive version of this fi gure is available online at http://healthmetricsandevaluation.org/gbd/visualizations/regional.
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cause, neonatal sepsis, has a UI that is nearly three times 
wider than the 11th ranked cause, COPD. Several causes 
have much larger UIs than adjacent causes in the rank 
list. Natural history models for whooping cough, measles, 
and syphilis have large UIs. This originates from con-
siderable empirical uncertainty on the estimation of 
incidence and case-fatality rates. By contrast, the HIV/
AIDS natural history model developed by UNAIDS has 
remarkably narrow uncertainty in many countries with 
large epidemics. Across the causes analysed with CODEm, 
where the validity of UIs were evaluated using out-of-
sample performance, there was also substantial variation 
across causes refl ecting both the coherence of the under-
lying data, and whether powerful explanatory covariates 
were identifi ed.
Figure 8 shows the composition of causes of death at the 
second level of aggregation (21 cause groups) for the 
21 GBD regions in 1990 and 2010 for both sexes combined. 
The regions were ordered by the mean age at death, a 
crude but informative measure of the demographic and 
epidemiological transition.40 At both time periods, there 
was substantial variation across regions in the relative 
importance of diff erent causes, with communicable dis-
eases and related causes being much more important in 
parts of sub-Saharan Africa and parts of Asia than in north 
Africa, and vascular diseases and cancer pre dominating in 
most other regions. By 2010, substantial progress was 
achieved, even in Africa, in reducing YLLs from com-
municable, maternal, neonatal, and nutritional causes 
particularly, although these still accounted for three out of 
four premature deaths in Africa. The predominance of 
vascular diseases as a cause of premature mortality in 
eastern Europe is clear from fi gure 8, especially compared 
with other developed regions, where cancer causes as 
much, if not more, premature death. The impact of the 
civil violence in Papua New Guinea in 1990 and the 
2010 earthquake in Haiti led to notable shifts due to war 
and disaster. The combination of road injuries, other un-
intentional injuries, and intentional injuries ranges from a 
high of 23% of YLLs in 2010 in central Latin America to a 
low of 6% in the Caribbean, nearly a four-fold variation.
Figure 9 shows the rank for every cause that was either 
in the global top 25 causes of YLLs in 2010 or appeared in 
the top 25 causes of YLLs for any region. The appendix 
(p 726) presents the same information for 1990. Diff erent 
colours represent diff erent bands of ranks (fi gure 9). 
Such heat maps help to visualise important variations in 
ranking of YLLs across regions. In both 1990 and 2010, a 
similar number of causes (60 or so) appeared in the 
rankings, but with very substantial regional variations. At 
the top of fi gure 9, causes highest in global rankings of 
YLLs, such as lower respiratory diseases, ischaemic heart 
Figure 8: Percentage of YLLs for all ages and both sexes combined by cause and region in 1990 and 2010
YLLs=years of life lost. (A) 1990. (B) 2010. An interactive version of this fi gure is available online at http://healthmetricsandevaluation.org/gbd/visualizations/regional.
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Oesophageal cancer 39 18 28 30 33 39 30 41 10 35 61 52 32 66 58 55 46 61 36 44 57 78
Rheumatic heart disease 40 36 41 49 60 36 34 36 28 41 51 28 24 48 18 48 32 36 37 43 44 49
Cause
Ischaemic heart disease 1 2 1 1 1 1 1 1 2 2 2 4 1 3 1 2 4 5 11 17 16 17
Lower respiratory infections 2 5 9 14 11 8 3 9 9 5 4 3 2 1 3 4 1 1 2 3 4 2
Cerebrovascular disease 3 1 2 3 3 2 2 2 1 3 10 1 3 5 2 3 9 8 7 14 13 12
Diarrhoeal diseases 4 57 61 76 54 80 55 44 61 23 12 6 14 8 7 7 3 3 3 4 2 3
Malaria 5 119 120 117 120 119 122 119 119 109 108 19 116 98 41 39 36 4 14 2 1 1
HIV/AIDS 6 65 40 56 26 44 20 3 23 8 11 9 20 9 38 5 13 10 1 1 5 4
Preterm birth complications 7 38 30 17 14 24 6 26 18 6 7 7 5 4 4 6 2 7 6 5 6 7
Road injury 8 10 11 6 5 7 4 5 4 4 3 5 7 2 6 11 11 19 12 11 11 9
Chronic obstructive pulmonary disease 9 12 5 7 4 10 11 13 3 11 14 17 11 23 17 27 5 27 27 29 25 32
Neonatal encephalopathy* 10 63 51 32 41 54 28 29 20 12 13 10 4 7 12 13 7 17 9 9 10 10
Tuberculosis 11 32 73 82 82 40 47 15 29 33 31 2 10 14 34 14 8 6 5 8 8 11
Sepsis 12 71 74 68 62 68 29 55 79 13 16 24 35 11 10 10 6 20 18 7 12 5
Self-harm 13 3 6 5 6 5 5 4 8 15 15 20 9 18 22 21 10 22 16 24 30 50
Congenital anomalies 14 24 23 13 19 20 8 17 11 9 9 12 8 6 5 12 12 14 13 15 7 15
Protein–energy malnutrition 15 67 76 79 73 82 52 84 59 38 19 38 50 19 25 19 16 16 29 6 3 6
Trachea, bronchus, and lung cancers 16 4 3 2 2 3 7 6 5 17 21 15 15 27 14 16 34 45 33 66 54 64
Cirrhosis of the liver 17 9 7 18 9 4 9 7 14 10 8 11 6 12 9 20 15 12 28 23 21 20
Meningitis 18 69 69 67 67 61 39 61 51 36 30 26 23 24 19 18 17 9 19 10 9 8
Diabetes mellitus 19 14 13 10 7 14 10 33 15 7 5 8 17 16 11 9 19 2 8 26 26 24
Interpersonal violence 20 49 50 38 12 31 12 8 31 1 1 16 13 10 20 8 27 24 4 18 17 23
Drowning 21 25 54 34 40 29 26 18 12 19 17 22 12 17 24 31 18 28 26 22 18 29
Liver cancer 22 7 20 28 30 21 33 37 6 34 26 18 29 31 29 30 57 21 41 45 47 30
Fire, heat, and hot substances 23 47 66 63 46 53 36 25 52 51 44 40 30 39 28 33 14 26 23 16 19 13
Chronic kidney diseases 24 13 22 21 16 22 16 31 22 16 6 14 16 13 16 22 25 11 17 32 36 31
Stomach cancer 25 6 15 25 34 13 18 12 7 24 18 33 19 15 27 34 43 31 50 52 56 60
Falls 26 21 21 29 29 17 40 21 16 28 27 29 33 33 32 36 23 42 55 27 31 19
Hypertensive heart disease 27 20 18 40 21 9 17 24 17 14 22 21 21 25 13 17 30 52 15 38 39 46
Maternal disorders 28 85 89 88 78 85 61 75 55 48 41 27 51 26 39 29 24 18 20 13 15 14
Colon and rectum cancers 29 8 4 4 10 6 13 14 13 21 28 31 31 34 33 25 55 50 40 56 63 63
Other cardiovascular and circulatory diseases 30 17 10 19 17 11 15 52 21 20 24 23 26 21 8 23 45 39 30 37 35 39
Breast cancer 31 16 8 8 13 12 14 19 24 22 25 30 28 32 26 28 47 35 38 46 55 59
Cardiomyopathy and myocarditis 32 28 24 26 20 15 19 16 34 18 38 37 22 28 15 32 38 40 22 35 32 38
Exposure to forces of nature 33 122 120 117 120 119 58 119 124 125 90 123 124 123 124 1 125 120 126 127 126 124
Exposure to mechanical forces 34 50 64 53 48 50 38 11 35 50 35 36 18 29 21 41 28 32 10 28 22 40
Typhoid and paratyphoid fevers 35 95 110 102 102 113 49 111 39 62 50 13 119 53 36 69 21 76 21 25 37 27
Leukaemia 36 19 19 15 22 23 22 28 19 29 20 32 27 20 23 38 48 23 49 68 62 66
Syphilis 37 102 101 83 101 87 82 98 74 61 57 48 66 30 47 24 41 41 31 12 14 18
Measles 38 106 105 101 108 105 103 110 103 106 93 34 83 58 94 106 20 54 35 19 38 22
Epilepsy 41 56 48 43 63 48 57 49 43 44 33 39 25 36 42 46 53 30 25 20 24 16
Asthma 42 42 60 50 57 59 65 50 49 54 46 25 41 62 30 45 26 13 32 40 34 33
Poisonings 43 64 65 42 25 47 68 20 25 95 58 57 34 60 40 85 31 15 43 30 28 43
Encephalitis 44 82 96 103 90 84 109 66 99 75 97 69 48 105 45 96 22 91 46 41 42 42
Cervical cancer 46 34 44 48 45 25 24 34 38 27 23 35 40 22 67 35 52 29 34 31 43 41
Pancreatic cancer 47 11 14 12 18 16 21 22 27 37 39 50 43 47 50 40 73 78 53 83 80 87
Brain and nervous system cancers 48 30 17 20 28 19 37 32 26 26 32 42 38 43 31 44 64 88 54 87 70 104
Non-Hodgkin lymphoma 49 23 26 16 24 33 31 51 37 40 40 43 45 35 46 42 51 47 45 48 58 54
Alzheimer's disease and other dementias 50 26 12 9 8 43 27 53 41 45 66 82 79 76 68 37 81 66 58 80 86 75
Tetanus 52 112 113 113 114 110 118 114 86 108 109 64 121 103 79 59 40 51 104 33 45 25
Acute hepatitis A 54 100 103 104 104 99 108 92 78 101 94 91 91 92 54 104 33 25 98 53 64 44
Alcohol use disorders 55 55 31 47 32 18 41 10 73 25 29 59 39 49 108 54 76 72 61 103 99 117
Kidney and other urinary organ cancers 57 29 25 24 23 27 32 27 36 57 47 75 49 63 57 58 85 80 76 84 85 79
Drug use disorders 58 72 34 22 15 57 69 23 64 71 52 70 37 40 35 52 93 56 24 59 72 69
Prostate cancer 63 31 16 11 27 26 23 42 72 30 34 77 59 42 56 26 100 68 47 75 79 74
Whooping cough 67 99 95 84 87 94 87 95 93 105 65 44 63 37 59 43 37 33 56 21 29 21
Gallbladder and biliary tract cancer 68 15 39 51 58 37 25 59 40 49 45 60 60 44 71 67 63 67 89 113 98 84
Iron-deficiency anaemia 72 77 83 90 81 90 74 89 90 63 43 85 73 38 114 15 75 55 44 54 27 26
Interstitial lung disease and pulmonary sarcoidosis 78 22 47 46 38 70 54 76 71 72 59 100 75 46 65 101 62 81 70 77 77 85
Sickle-cell disorders 80 109 94 107 86 104 105 107 120 80 88 122 117 102 64 51 108 115 100 67 20 28
Malignant melanoma of skin 91 73 38 23 44 45 71 56 77 70 77 106 72 84 103 94 117 48 88 116 113 111
African trypanosomiasis 106 122 120 117 120 119 125 119 124 125 127 123 124 123 124 123 125 120 124 76 23 68
Gl
ob
al
H
ig
h-
in
co
m
e
As
ia
 P
ac
ifi
c 
W
es
te
rn
 E
ur
op
e
Au
st
ra
la
sia
H
ig
h-
in
co
m
e
N
or
th
 A
m
er
ic
a 
Ce
nt
ra
l E
ur
op
e
So
ut
he
rn
 
La
tin
 A
m
er
ic
a
Ea
st
er
n 
Eu
ro
pe
Ea
st
 A
sia
Tr
op
ic
al
 
La
tin
 A
m
er
ic
a
Ce
nt
ra
l 
La
tin
 A
m
er
ic
a
So
ut
he
as
t A
sia
Ce
nt
ra
l A
sia
An
de
an
 
La
tin
 A
m
er
ic
a
N
or
th
 A
fri
ca
an
d 
M
id
dl
e 
Ea
st
  
Ca
rib
be
an
So
ut
h 
As
ia
O
ce
an
ia
So
ut
he
rn
 
su
b-
Sa
ha
ra
n 
Af
ric
a 
 
Ea
st
er
n 
su
b-
Sa
ha
ra
n 
Af
ric
a
Ce
nt
ra
l 
su
b-
Sa
ha
ra
n 
Af
ric
a
W
es
te
rn
 
su
b-
Sa
ha
ra
n 
Af
ric
aRanking Legend
91–176
1–10 11–20 21–30
31–50 51–90
Figure 9: Regional ranking of leading causes of years of life lost (YLLs), 2010
Causes in the fi gure are ordered according to global ranks for causes. The fi gure shows all causes that are in the 25 leading causes in at least one region. Ranks are also colour-shaded to indicate rank 
intervals. *Includes birth asphyxia/trauma. An interactive version of this fi gure is available online at http://healthmetricsandevaluation.org/gbd/visualizations/regional.
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disease, and stroke were the top ten causes of premature 
death in almost all regions in 2010, as were complications 
of preterm birth in all regions except Europe, high-
income Asia Pacifi c, and east Asia. The massive eff ect of 
HIV/AIDS on mortality in most developing regions by 
2010 was also clear, with north Africa and Middle East, 
east Asia, central Asia, and southern Latin America being 
notable exceptions. Malaria was a leading global cause 
but a minor cause in most regions outside sub-Saharan 
Africa and Oceania. Road injury was a remarkably 
consistent cause of YLLs; its lowest regional ranking is 
19th in Oceania and it was in the top fi ve causes in eight 
regions. All the neonatal causes and tuberculosis were 
important causes in some developing regions but minor 
causes in the more epi demiologically and demographically 
advanced regions. Figure 9 also highlights causes that 
were not in the top 25 global rankings but were important 
in selected regions. In some cases, these regional patterns 
gave a glimpse of future patterns and trends. Suicide was 
a top ten cause in the eight regions with the most 
advanced health transition. Other causes that seemed to 
be strongly related to the epidemiological and demo-
graphic tran sition included colon and rectum cancer, 
breast cancer, pan creatic cancer, brain cancer, non-
Hodgkin lymphoma, Alzheimer’s disease, kidney cancer, 
and prostate cancer. Other diseases had a more focal 
regional pattern that was not directly related to the broad 
health transition. More notable examples highlighted by 
multicoloured rows include: cirrhosis, diabetes, inter-
personal violence, sickle-cell disease, whoop ing cough, 
poisonings, oe sophageal cancer, drug use, gallbladder 
cancer, malig nant melanoma, and African trypano-
somiasis. Generally, the distribution of ranks by cause for 
YLLs was much more heterogeneous than for YLDs.52 
This was true for both time periods and suggests marked 
regional variation in disease and injury control priorities 
to improve survival.
Marked variation was noted in cancer rates by site and 
overall across regions in 2010 (fi gure 10). Figure 10 
shows crude death rates to highlight the mixture of 
cancers recorded in health systems of every region but 
to remove the eff ect of variation in population size 
across regions. Crude rates are aff ected both by variation 
in age-specifi c and site-specifi c death rates and by 
population age-structure. In general, crude cancer death 
rates were higher in the regions with a more advanced 
demographic transition. But regions such as high-
income Asia Pacifi c had a substantially diff erent cancer 
profi le from that in western Europe due to breast cancer, 
liver cancer, and stomach cancer along with a number 
of smaller cancers. At the other end of the epidemio-
logical spectrum, crude cancer rates in three of the sub-
Saharan African regions were the lowest. Central Latin 
America, tropical Latin America, and Andean Latin 
America have low cancer rates overall, whereas the 
Caribbean had higher rates than expected for its 
demographic transition.
Discussion
The GBD 2010 is the most comprehensive and system-
atic analysis of causes of death undertaken to date. The 
addition of time trends over 1980–2010 and quantifi ca-
tion of uncertainty increases both the utility and the 
methodological rigour of the results. The global health 
community can now draw on annual estimates of 
mortality, by age and sex, for 21 regions of the world, for 
each year from 1980 to 2010, for 235 separate causes, 
each with 95% UIs to aid interpretation. These estimates 
of cause of death at the regional level are constructed 
from separate estimates of cause of death at the country 
level for 187 countries. No such resource for policy 
makers, donors, or scholars currently exists. At the most 
aggregate level, we have documented great changes in 
cause of death structure in regions such as central Latin 
America and tropical Latin America. We have also 
identifi ed regions, such as eastern Europe and central 
Asia, where mortality has increased profoundly over the 
past two decades but the cause of death structure has not 
changed dramatically, at least for leading causes.
The shifting pattern of the number of deaths by cause 
across time, regions, and age groups is consistent with the 
three key drivers of change: rising total population, rising 
average age of the world’s population, and the broad epi-
demi ological transition. For communicable, maternal, 
neo natal, and nutritional causes, the increase expected 
because of population growth alone is reversed by popu la-
tion ageing and decreases in age-sex-specifi c death rates. 
By contrast, both population growth and ageing are driving 
up the number of deaths from non-communicable 
diseases and injuries more than the decreases expected 
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Figure 10: Cancer death rates in 2010 for all ages and both sexes combined by cause and region
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because of lower age and sex-specifi c rates. Overall, these 
factors are leading to a shift from a pattern dominated by 
the main infectious disease killers of children (such as 
lower respiratory infections, diar rhoea, malaria, and 
menin gitis), and tuberculosis and maternal causes in 
younger adults, to one dominated by the non-com-
municable causes over age 40 years. Quite diff erent 
regional stories are overlaid on this broad pattern. Injuries 
have very distinct regional patterns, with violent death 
being much more common in selected regions. The HIV 
epidemic has had massive eff ects in eastern and southern 
sub-Saharan Africa. Diabetes has a major eff ect in central 
Latin America, the Caribbean, north Africa the Middle-
East, and Oceania. Theories of the epidemiological tran-
sition need to be nuanced to capture these distinct trends 
and patterns that suggest diff erent health trajec tories in 
diff erent regions in the coming decades. Our fi ndings are 
also diff erent from many published studies on causes of 
death in some age groups or for specifi c causes; these 
diff erences warrant careful discussion.
The HIV epidemic has greatly changed the pattern of 
causes of death between 1990 and 2010 in eastern and 
southern sub-Saharan Africa. We estimated that, in 2010, 
1·47 million deaths were due to HIV/AIDS compared 
with UNAIDS estimates of 1·77 million, which is a 
21% diff erence at the global level. For specifi c countries 
and regions, the diff erences are much larger. We used 
UNAIDS estimates as the input to CoDCorrect for most 
countries, so the diff erence is almost entirely due to the 
juxtaposition of evidence on levels of all-cause mortality 
and natural history model estimates of HIV/AIDS deaths. 
We believe that this is an important strength of the 
burden of disease approach. Some diff erences are also 
due to the data from Thailand, where in the 2012 UNAIDS 
assessment mortality doubled compared with their 
2010 assessment. Even the 2010 UNAIDS assessment 
was twice the magnitude recorded in two studies of 
national verbal autopsy and vital registration data.66,67 We 
chose to use the 2010 UNAIDS revision esti mates for 
Thailand because of the implausible nature of the 
2012 revision estimates. Nigeria is another example of a 
country whose estimates contribute to a substantial part 
of the diff erences between global data from UNAIDS 
and GBD 2010. Since Nigeria is a country with a large 
population, a major HIV/AIDS epidemic, and poor data 
quality, when we fi t our HIV/AIDS estimates for Nigeria 
into the country’s all-cause mortality levels our estimates 
are much lower (27·9% in 2010) than those of UNAIDS 
and this large diff erence in death is refl ected at the global 
level. The uncertainty distributions for UNAIDS esti-
mates of mortality in some countries in sub-Saharan 
Africa are implausibly narrow; for example, at the peak of 
the epidemic in Malawi, the UI for deaths at all ages 
provided by UNAIDS varied by plus 8·5% or minus 
8·1%. Our UIs based on the UNAIDS fi gures were also 
implausibly narrow. Improved estimation of mortality 
from HIV/AIDS including uncertainty in the future will 
come both from continued progress in the estimation of 
the timecourse of the HIV epidemic by UNAIDS and 
from further data on the levels of adult mortality in some 
key countries such as Nigeria.
On the basis of a single-cause analysis, Murray and 
colleagues25 reported 1·24 million malaria deaths in 
2010 of which 42% were in individuals older than 5 years. 
These estimates had very large UIs; for example, the 
number of deaths in those older than 5 years in sub-
Saharan Africa was estimated to range from 307 000 to 
658 000. Large uncertainty in the results refl ected both the 
sparse data available on causes of death in adults and the 
large variation in results across diff erent models included 
in the fi nal ensemble model. In these GBD 2010 results, 
where the sum of cause-specifi c estimates must equal the 
number of deaths from the demographic analysis for each 
country-age-sex-year, the number of malaria deaths in 
2010 was estimated to be about 5% less or about 
1·17 million. For deaths in children younger than 5 years, 
the change was from 714 000 to 676 000. For deaths in 
individuals older than 5 years, the change was from 
524 000 to 494 000. Our fi nding of substantial deaths due 
to malaria in populations older than 5 years is driven by 
the evidence from verbal autopsy studies in endemic 
areas.25 Validation studies suggest that verbal autopsy 
studies overestimate adult deaths at low malaria cause 
fractions and underestimate adult malaria deaths when 
malaria deaths are common.68 The fi ndings of adult deaths 
from malaria are consistent with data of hospital discharge 
and death in endemic areas but remain controversial.69–72 
Our UI for global deaths in individuals older than 5 years 
from malaria was 365 356 to 643 977, partly depicting the 
uncertainty in the underlying data sources.
An innovative dimension of the GBD 2010 has been the 
addition of estimates of deaths due to diff erent diar rhoea 
and lower respiratory infection pathogens. These are 
important both for the prioritisation of existing treatments, 
such as rotavirus or pneumococcal vaccines, and for the 
development of future technologies. Making sense of the 
data by aetiology is extremely challenging. For diarrhoea, 
many pathogens can be cultured from the stool of 
individuals without diarrhoea. Studies such as the Global 
Enterics Multi-Center Study (GEMS)73 are trying to 
estimate relative risks of diarrhoea in the presence of 
diff erent pathogens. In the available obser vational data 
that do not use this relative risk approach, the relation 
between the prevalence of a given pathogen and the num-
ber of pathogens tested is strong. Studies testing only one 
pathogen eff ectively report higher fractions due to a patho-
gen than do studies that test for multiple pathogens. This 
fi nding is probably caused by the frequency of various 
pathogens in the same stool sample and rules for allocating 
shares of diarrhoea to pathogens such that the sum of the 
pathogen cause fractions total to 100%. In our analysis, we 
adjusted study results to be equivalent to studies reporting 
two to eight pathogens. Because of both the huge hetero-
geneity of results and the variation in the number of 
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pathogens tested across studies, great caution should be 
used in interpreting our fi ndings on the diarrhoea aetiol-
ogies. When large multicentre studies such as GEMS pub-
lish their results, their fi ndings will be an important 
addition to this analysis; future revisions of the GBD 
should make use of these results as they become available. 
Never theless, our results are notably diff erent from widely 
cited fi ndings. For example, we reported 173 000 deaths 
due to rotavirus in children younger than 5 years and 
78 000 deaths in individuals older than 5 years in 2010; 
these fi ndings contrast with claims from WHO of 
453 000 rotavirus deaths in children younger than 5 years 
alone in 2008.74 Higher numbers were probably reported 
by WHO for three reasons: higher all-cause global deaths 
in children younger than 5 years than currently esti mated 
by UNICEF or the GBD 2010; a much higher fraction of 
deaths in children younger than 5 years attributed at the 
time to diarrhoea; and a higher fraction of diarrhoea attrib-
uted to rotavirus. Because rotavirus remains an important 
cause of death in many countries, the GBD estimates by 
country, when released, will be an important method to 
assist in understanding where its burden is greatest.
For respiratory pathogens, even greater challenges exist. 
In many observational studies, no pathogen is identifi ed 
in a substantial fraction of cases. Even in severe cases that 
lead to hospital admission, the case-fatality rate is likely to 
vary substantially by pathogen, which con founds the 
analysis. The substantial diff er ences in our results from 
published assessments by O’Brien and colleagues35 for 
pneumococcal lower respiratory infec tions, Nair and 
colleagues75 for RSV, and Watt and colleagues76 for Hib 
deserve exploration. Our fi ndings of 168 000 deaths due to 
pneumococcal lower respiratory infection in children 
younger than 5 years in 2010 and 381 000 in 1990 contrast 
sharply with the 826 000 for the year 2000 published by 
O’Brien and colleagues.35 in 2009, these investigators used 
an estimate of 10·6 million deaths in children younger 
than 5 years from all causes for the year 2000, which 
contrasts with our estimate of 9·4 million and UNICEF’s 
estimate of 9·6 million. They used a higher estimated 
fraction of deaths in children younger than 5 years due to 
lower respiratory infections than in our study, 27% and 
18%, respectively. The fraction of lower respiratory deaths 
in children younger than 5 years due to pneumococcal 
pneumonia was 35·8% (UI 16·0–50·9) in 2000 compared 
with 19·8% (16·1–24·8) in the GBD 2010 for 2010. The 
95% UIs for these cause fractions substantially overlap. 
Diff erences in the mean estimate result largely from the 
exclusive use by O’Brien and colleagues of the results of 
four vaccine trials in the Gambia, the Philippines, the 
USA, and South Africa to estimate an average fraction of 
pneumonia in children younger than 5 years. Although 
they reviewed the literature, they chose not to use the 
published obser vational studies. These observational data 
suggest sub stantial variation across regions; for example, 
pneumo coccus might be less common in south Asia. We 
used both the trials and observational data to generate 
diff erent breakdowns by pathogen by region giving extra 
weight to the trials; our fi ndings, however, still showed 
variation by region and age. For RSV lower respiratory 
infections, our fi ndings of 234 000 deaths in children 
younger than 5 years in 2010 and 520 000 in 1990 are 
notably higher than the 66 000 to 199 000 deaths for the 
year 2005 reported by Nair and colleagues75 in 2010. They 
reviewed the published studies on RSV but chose, on the 
basis of expert opinion, to assume no RSV deaths in 
individuals older than 2 years;75 the scientifi c literature, 
however, records deaths in those older than 2 years.77,78 
Data on hospital admission in the USA, for example, 
suggests substantial burden of severe RSV at least in the 
ages 3–5 years. Other investigators79,80 argue that RSV is an 
important and often missed pathogen causing severe 
lower respiratory infections in elderly people. Studies, 
however, vary markedly in their sampling, culturing, and 
identifi cation protocols, which might also account for 
some hetero geneity. Most studies show high fractions of 
neonatal lower respiratory deaths due to RSV, so the extent 
to which RSV is a major cause of post-neonatal lower 
respiratory deaths needs the most attention. For deaths 
due to Hib lower respiratory in fection, Watt and col-
leagues76 published in 2009 for the year 2000, an estimate 
of 292 000 deaths that compares well with our fi nding of 
184 000 (95% UI 154 053–219 456) in 2010 and 447 000 
(385 717–506 594) in 1990. The similarity of the result, 
however, is somewhat misleading. They used a much 
higher estimate of all-cause under-5 mortality and a higher 
cause fraction due to lower respiratory infection than we 
used. In other words, we estimated a larger fraction of 
lower respiratory infection deaths in children younger 
than 5 years due to Hib than did Watt and colleagues. The 
main reason for this diff erence is that Watt and colleagues 
assumed that Hib in individuals older than 2 years does 
not cause death; the available obser vational data,81–84 how-
ever, show Hib mortality at all ages. For example, results 
from the study in Japan84 showed severe cases of hospital-
acquired and community-acquired pneumonia related to 
Hib, the diff erences in these assessments for all the 
respir atory pathogens is even more striking. New 
multicentre studies such as PERCH85 will hopefully 
provide much needed data to strengthen the analysis of 
pathogens by region.
We estimate that in 2010 1·20 million deaths were due 
to tuberculosis, about 14% more than the WHO estimate 
of 1·05 million (2011 WHO TB Report). Our analysis and 
that of WHO use fundamentally diff erent methods but 
do not yield, at the aggregate level, substantially diff erent 
conclusions. The key diff erence lies in how the case-
detection rate in every country was estimated; WHO 
used locally informed expert consultation to assess both 
under-diagnosis and under-reporting whereas we used a 
statistical model to try and estimate the case detection 
rate. Our models also captured more of the temporal and 
spatial correlation structure in the cause of death data 
yielding quite diff erent estimates than did the WHO 
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where data were strong (eg, Japan and Thailand). These 
diff erences result in important variations between our 
estimates and those from WHO at the country and 
regional levels that deserve further investigation. Despite 
these variations, for some countries, such as Ecuador, 
our estimates, WHO estimates, and the cause of death 
data were in close alignment. Assessments at the global 
and regional level point to substantial continued and 
sustained progress in reducing tuberculosis mortality. 
Our higher levels of mortality for tuberculosis in 2010 
suggest that tuberculosis should remain a major priority.
Deaths due to maternal causes have been reported 
in various studies86,87 in the peer-reviewed scientifi c 
literature and UN reports.88 These studies, however, 
focused on the maternal mortality ratio. ICD 10 rules 
recommend that pregnancy-related deaths due to HIV 
should be included in the computation of the maternal 
mortality ratio but reported in cause of death tabulations 
for HIV. The GBD 2010 follows this convention so that 
our 255 000 maternal deaths in 2010 do not include 
18 970 HIV-related deaths in pregnancy included in the 
HIV totals. We also revised the method used to estimate 
the fraction of maternal deaths related to HIV/AIDS in 
this study compared with Lozano and colleagues.23 In 
GBD 2010, our estimates of the fraction of maternal 
deaths related to HIV/AIDS come from a review and 
statistical analysis of available data that provide a detailed 
breakdown of maternal deaths. Further, the deaths due to 
maternal causes reported here are after the application of 
the CoDCorrect algorithm, which is a strength of the 
comprehensive burden of disease approach. The global 
number of deaths due to maternal causes was reduced by 
9·8% through the application of CoDCorrect. The revised 
approach for maternal mortality presented here also 
highlights the major causes of maternal death. The largest 
specifi c cause of maternal death is maternal haemorrhage 
accounting for 23% of deaths in 2010, followed by hyper-
tensive disorders causing 18%, abor tion causing 15%, 
sepsis causing 9%, and obstructed labour causing 4%. 
These results contrast with various estimates reported by 
WHO—one estimate for 2005, which is based on 
35 197 deaths reported in various published studies89 and 
one largely based on vital regis tration data for 2008.16 The 
2005 WHO report estimated that abortion caused only 8% 
of maternal deaths but 14% in the 2008 study.16 There are 
also substantial diff er ences for other maternal causes as 
well. Our fi ndings are based on a larger set of published 
studies, including reports from 18 countries such as India, 
South Africa, Bangladesh, Ghana, and Pakistan, which 
contribute 22 943 additional maternal deaths on the 
detailed causes of maternal death.
For deaths in children younger than 5 years, our results 
diff er from those published by CHERG20 for the same year 
in several key ways: CHERG estimated 1·40 million deaths 
due to lower respiratory infection compared with 847 000 in 
our study; CHERG estimated 801 000 for diarrhoeal 
diseases versus 666 000 in the GBD 2010; for malaria 
CHERG estimated 564 000 versus 676 000 here. Within the 
neonatal causes, there are also striking diff erences in the 
composition of specifi c neonatal causes, with CHERG 
estimating much higher fractions due to preterm birth 
complications and lower fractions due to sepsis and other 
disorders. In exploring these diff er ences, it is crucial to 
distinguish between the neonatal age group (under 
28 days) and causes arising during the neonatal period that 
can cause mortality both under 28 days and in the post-
neonatal period and less commonly over age 1 year. 
Understanding the source of the diff erences for neonatal 
causes, however, is chal lenging. Diff erences must arise 
from any or all of the following: the datasets used, the 
adjustments to the data, and the modelling strategies. 
In their analysis of post-neonatal child mortality 
(1–59 months), CHERG reported using vital registration 
data for 578 country-years between 1998 and 2009, whereas 
we used 1125 country-years for that period. They used 
113 study years between 1980 and 2008; by contrast, we 
used 294 years. CHERG used a reduced number of studies 
because of their decision to use only studies that report on 
six major causes. The largest diff erences and the ones 
likely to explain the diff ering results lie in the modelling 
strategy. For a single cause such as diarrhoeal diseases or 
lower respiratory infections, we developed one ensemble 
model using all the data. The one ensemble model 
included component models with a wide variety of 
functional forms but all included age group fi xed eff ects. 
CHERG tested and developed four diff erent models with 
no relation between them: for under-5 mortality rates 
(UFMR) lower than 35 for babies younger than 1 month, 
for UFMR higher than 35 for babies younger than 1 month, 
for UFMR lower than 35 for children aged 1–59 months, 
and for UFMR higher than 35 for children aged 
1–59 months. The relations between covariates in these 
diff erent models were estimated as completely inde-
pendent. Covariate selection was done for every cause of 
death independently for each of the four models. They 
used multinomial logistic models to make estimates for 
six causes of death simultaneously, a method found to 
perform worse than modelling causes individually and 
then scaling to all-cause mortality (appendix pp 146–148). 
Their model structure does not allow for spatial or 
temporal patterns in the residuals, probably substantially 
reducing model performance.22 Model performance is 
diffi  cult to assess and compare with ours: they reported 
undertaking a cross-validation study but no metrics of 
model performance were reported such as the coverage of 
their UIs or a measure of prediction error. Further, in their 
cross-validation study they left out 10% of the data at 
random; as shown in previous studies,23 this is the easiest 
task for prediction. A much harder task, which was used in 
the GBD 2010, is to leave out long sequences or all data for 
some countries and see how well the models perform. 
Additionally, leaving out data for one cause without also 
dropping it for the other causes in that country-year makes 
for an even simpler task in a multinomial logistic model 
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such as the one CHERG used. The high levels of mortality 
for lower respiratory infections might be related to the bias 
in physician diagnosis of verbal autopsies, which was 
demonstrated in a rigorous validation study.68 Although 
this study68 used physician-certifi ed verbal autopsy data on 
lower respiratory infections, by separating the data into 
four components and not including country random 
eff ects in their models, the bias towards higher such 
infections in verbal autopsy studies might have had a 
larger eff ect on their estimation procedure. Finally, the 
CHERG estimation strategy uses multinomial models for 
a subset of models and then adds on estimates for selected 
causes in selected countries such as HIV/AIDS, measles, 
tetanus, and malaria. The diff erential treatment of some 
causes and not others in the modelling strategy might also 
have caused distortions in the results. Interestingly, given 
the substantial diff erence in modelling approaches, the 
results for 2010 between the two approaches were actually 
surprisingly close.
The health-related MDGs place special priority on 
reducing under-5 mortality, maternal mortality, and deaths 
from HIV, tuberculosis, and malaria. These causes 
collectively accounted for 42·4% of YLLs in 2010. Even 
though the computation of YLLs heavily weights deaths in 
children younger than 5 years, more than half (57·6%) of 
global YLLs in 2010 were due to non-MDG diseases and 
injuries. Important global causes that are not included in 
the MDGs include ischaemic heart disease, stroke, COPD, 
road traffi  c injuries, and self-harm. The predom inance of 
these causes in YLL rankings is not merely a volume issue: 
many of those who die from these causes do so at young 
adult ages. A more holistic view of preventable mortality 
within the MDG platform would argue that these causes 
ought to be included in any evidence-based framework for 
reducing avoidable deaths. Examination of the trends from 
1990 to 2010 in dicated that the MDG-related YLLs were 
declining at 2·0% per year, whereas the non-MDG related 
YLLs were increasing at 0·8% per year. Population ageing 
and the substantial if incomplete progress in reducing age-
specifi c death rates from the MDG related causes all 
suggest that these trends will continue. Indeed, if they do, 
then non-MDG related causes are likely to account for 
more than two-thirds (67·6%) of YLLs by 2025. These 
fi ndings highlight the importance of looking more critically 
and comprehensively at what are the leading causes of 
death and YLLs worldwide, and how these are changing. 
Our analyses, for the fi rst time, allow such comparative 
assessments and are important inputs into discussions 
about goals and targets for the post-MDG era.90 The rapid 
and global rise in premature death from leading non-
communicable diseases argues strongly for inclusion of 
these disorders, and their principal causes, in this agenda, 
particularly in view of their close relation to poverty 
reduction goals.91–96 It also stresses the need to understand 
the eff ective and aff ordable options for prevention of non-
communicable diseases and injuries and treatment includ-
ing both medical and surgical interventions.97
Our study suggests that the number of deaths where 
chronic kidney disease is the ICD underlying cause of 
death increased by 82% from 1990 to 2010. In addition to 
these deaths, a reduced glomerular fi ltration rate (GFR) 
has been associated with an increased risk of death.98 
Even chronic kidney disease stages II–IV are associated 
with increased risk of death. The directly coded deaths 
due to chronic kidney disease that we estimated probably 
capture only those deaths due to end-stage renal disease. 
Other diseases such as diabetes are also associated with 
an increased risk of death from other causes. For 
diabetes, the risk factor analysis99 provides an assessment 
of all mortality associated with hyperglycaemia. This 
number is substantially larger than the number of deaths 
directly coded to diabetes estimated here.
Those who study the health eff ects of war will be 
surprised by the 17 670 deaths related to direct confl ict 
estimated for 2010. This number should be interpreted 
with great caution. First, in the ICD cause list, only direct 
deaths are assigned to this cause; 17 670 is not the total 
number of deaths related to confl ict, which would include 
indirect deaths mediated through various mechanisms 
such as the destruction of health-care infrastructure.100 
Second, the number of direct deaths varies substantially 
from year to year. During 1990–2010, direct deaths peaked 
at 496 400 in 1994 with a low in 2001 of 14 700 and 17 700 in 
2010. In 2011, because of the confl ict in Libya, for example, 
direct deaths were likely to have been much higher, closer 
to 61 000. For episodic events such as wars or natural 
disasters, it is important to consider the burden of disease 
over longer periods of time to fully appreciate their eff ect 
on human populations.
For the fi rst time in the GBD enterprise, we included 
deaths that were mainly related to hepatitis B, hepatitis C, 
alcohol, and other causes as disaggregated causes for 
cirrhosis and liver cancer. These categorical breakdowns 
are not counterfactual assessments but rather an attempt 
to assign deaths to the primary or dominant cause. Inter-
actions exist between hepatitis and alcohol consumption, 
such that assessment of these conditions as a risk factor 
would give diff erent results. Nevertheless, this categor-
ical attribution provides a useful assessment of the 
magnitude of direct burden, particularly for guiding 
intervention priorities. The total number of deaths due to 
hepatitis B in 2010 was estimated to be 786 000 and those 
due to hepatitis C 499 000. If all deaths related to these 
diseases were directly counted in the main GBD 2010 
cause list, hepatitis B would be the 15th ranked cause of 
death and hepatitis C would be the 25th ranked cause of 
death. Cirrhosis rates vary greatly across countries, with 
Egypt having the highest level related to an iatrogenic 
epidemic of hepatitis C that began as early as the 1920s.101 
Some regions have high rates such as central Asia, 
Oceania, eastern and western sub-Saharan Africa, 
eastern Europe, and central Latin America. Not all this 
regional and country variation can be explained by 
hepatitis B, hepatitis C, or total alcohol consumption. For 
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example, high rates in eastern Europe might be related to 
the content rather than volume of alcohol consumed. 
Theories on this distinction include hepatotoxic alcohol 
constituents in homemade poor quality alcohol, which is 
common in these regions.102 Given that much of the 
burden of cirrhosis can be preventable, its substantial 
global mortality deserves more policy attention.
The much more detailed categories of causes of death for 
injuries in the GBD 2010 provide some important insights 
into the global epidemic of road injuries. The number of 
deaths increased from 908 000 in 1990 to 1·329 million in 
2010. These results are similar to the 1·237 million 
reported for 2007 by WHO.103 The com position of this 
increase in road injuries, however, has diff ered by sub-
cause. Road deaths to pedestrians were the major cause, 
rising from 284 000 in 1990 to 461 000 in 2010. Road deaths 
of occupants in motorised vehicles with three or more 
wheels and road deaths of riders of motorised vehicles 
with two wheels each have also increased by about 
200 000 in the past two decades. Regional detail shows 
road deaths in east Asia, south Asia, and eastern and 
western sub-Saharan Africa rapidly escalating over the past 
two decades, whereas in high-income areas with a history 
of road safety pro grammes such as western Europe and 
high-income North America, road deaths have decreased.
Violence as a cause of death is one of the most 
heterogeneous across diff erent regions. Crude death rates 
for violence are lowest in high-income Asia Pacifi c at one 
per 100 000. The rate in 2010 in high-income North 
America dominated by the USA of seven per 100 000 was 
nearly seven times higher than high-income Asia Pacifi c, 
western Europe, or Australasia. But in tropical Latin 
America, the rates are substantially greater still, at 30 per 
100 000, and even higher in central Latin America and 
southern sub-Saharan Africa, at 33 per 100 000. The huge 
variation in violence raises important questions about the 
origins and sociopolitical context of violence, the drivers of 
change in violence-related mortality, and the eff ectiveness 
of public health strategies in reducing deaths from 
violence. In men from tropical Latin America, violence is 
the number one cause of YLLs. In 2010, men in the 
20–24 years age group alone had 653 600 YLLs, three 
quarters the size of the 824 000 YLLs in men in high-
income North America of all ages combined.
An important dimension to the GBD is the requirement 
that estimates of causes of death sum to estimates of 
all-cause mortality. The discipline of requiring this 
internal consistency has been a hallmark of burden of 
disease analysis since the GBD 1990. As quantifi ed in the 
appendix (p 144) the eff ect is to reduce the number of 
deaths estimated for many causes compared with single-
cause analyses. The correction factor is an indication of 
inconsistency at the country-age-sex-year level between 
demographic analysis and the cause-specifi c analyses. We 
believe that for causes for which the magnitude of these 
corrections is comparatively large, future research should 
be targeted to try to build a better understanding of the 
strengths and weaknesses of the various data sources, 
whether epidemiological or demographic. In some sense, 
the CoDCorrect ratios can help direct attention to settings 
in which the data are the most inconsistent and our 
knowledge the most uncertain. The substantial diff erence 
between single-cause-model estimates and those pre-
sented here raises questions about the value of publishing 
single-cause assessments. Some organisations such as 
WHO have in recent years been producing both types of 
assessments: WHO with CHERG produces estimates for 
16 major causes of child death but also publishes single-
cause estimates for tuberculosis, HIV/AIDS, malaria, 
maternal mortality, and other causes. Should leading 
scientifi c journals continue to review and publish studies 
on single-causes of death? Due con sideration of the value 
of single-cause models to bring attention to neglected 
issues or stimulate innovation in methods or new data 
collection will need to be balanced against the greater 
robustness of more comprehensive assessments such as 
those presented here.
A study of this size and scope has many limitations. The 
ambition to estimate mortality from 235 causes with 
uncertainty for 187 countries over time from 1980 to 
2010 means that many choices about data sources, quality 
adjustments to data, and modelling strategies had to be 
made. We highlight some key limitations. First, data on 
cause of death, even in settings with medical certifi cation, 
might not always accurately cap ture the underlying cause 
of death. Results from autopsy studies104–106 have shown 
that medically certifi ed causes of death might be incorrect. 
Second, our approach to garbage code redistribution, 
although an improvement over past eff orts, could benefi t 
strongly from more empirical information on mis-
classifi cation obtained in places where gold standard 
cause of death assignment is possible. We were not able to 
develop uncertainty dis tributions around garbage code 
redistribution algo rithms; to the extent that this is poorly 
known, our UIs for some causes might be underestimated. 
Third, we made extensive use of verbal autopsy data, 
especially in low-income settings. Verbal autopsy vali-
dation studies68 suggest that verbal autopsy is accurate for 
some causes such as breast cancer, drowning, or road 
injury, but less accurate for other causes. Verbal autopsy 
perform ance for some key causes of child death such as 
lower respiratory infections is particularly poor. Much 
could be learned about causes of death in countries where 
death certifi cation is poor through the more widespread 
testing and application of recent advances in verbal 
autopsy methods, which greatly reduce hetero geneity in 
diagnostic practices across populations in which verbal 
autopsy is currently used.107 Fourth, for some causes of 
death such as kidney cancer, poisonings, or paralytic ileus, 
only weak covariates have been iden tifi ed that explain the 
spatial or temporal variation in the cause. Inevitably, 
model estimates for these causes will have wide UIs. The 
use of negative binomial models and fi xed proportion 
models where data are extremely weak is another area for 
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which better data and improved methods could strengthen 
the overall fi ndings. Fifth, where natural history models 
have been used, their validation is extremely diffi  cult at 
present. Natural history models are in principle used 
when concerns exist that data on direct cause of death are 
potentially biased. Improvements in data on cause of 
death for some causes such as HIV/AIDS might allow in 
the future oppor tunities to validate natural history models 
in selected countries. Where natural history models have 
been used, these approaches potentially will tend to yield 
higher estimates than those using more empirical 
strategies such as CODEm. Sixth, our use of CODEm for 
most major causes of death means that our UIs have in 
most cases been shown to be valid, but for causes where 
we have had to use other methods such as negative 
binomial, fi xed proportion, or natural history models, the 
UIs have not been independently validated. Seventh, 
CODEm can be improved in the future by including an 
even broader set of model families. Ultimately, the greatest 
limitation is the availability of data on cause of death itself. 
Finally, in cases where expert opinion and the available 
data diverge, we tended to follow the avail able data. 
Examples of this practice include estimating deaths from 
malaria in individuals older than 5 years or deaths from 
Hib in those older than 2 years. Subsequent more detailed 
studies might affi  rm that expert opinion was correct and 
the available data substantially biased. Nevertheless, we 
believe that to follow the balance of the available data that 
meet our quality criteria is important.
Improving data collection on cause of death in the 
future is the most direct and obvious pathway to 
improved estimation of global, regional, and national 
causes of death with narrower UIs. Improved verbal 
autopsy methods108–111 mean that it might soon be feasible 
to apply them routinely to generate comparable data on 
cause of death cost eff ectively in populations in which 
we are still substantially ignorant about the leading 
causes of death. Opportunities for strengthening death 
registration, cause of death certifi cation, and the more 
widespread use of verbal autopsy exist. Some countries 
have civil registration systems that capture less than 
70% of deaths; the priority in such cases is to improve 
certifi cation and coding of cause of death. Other 
countries such as Saudi Arabia have functioning civil 
registration run by Ministries of the Interior that are not 
fully used by Ministries of Health. Collectively, the global 
health community would benefi t enormously by placing 
much greater priority on strengthening vital registration 
systems to improve measurement of cause of death. 
This is now the key focus of the Health Metrics Network 
and it is reasonable to expect that substantial progress 
can be made with appropriate leadership, attention, and 
collaboration among global development partners.112
In the GBD 2010, a substantially new set of analytical 
approaches and methods have been developed and 
applied. These methods range from improved diagnostic 
redistribution methods to CODEm and CoDCorrect, 
draw ing on information for almost a billion deaths and 
time series for hundreds of covariates that aff ect mortality. 
This is a massive endeavour, but, with appro priate invest-
ment and leadership, updating results as new data on 
causes of death or alternative covariates become available 
will be much more feasible than hitherto. Rather than 
huge periodic revisions of the GBD every decade, it is now 
feasible to conduct annual updates so that the consumers 
of health intelligence have the most recent and compre-
hensive information on comparative causes of disease 
burden available where and when it is required to help 
guide public health decision making. Public health 
priorities everywhere are changing, or soon will be, as 
large and avoidable causes of disease burden become 
more common with develop ment. To not have strategically 
important and com parable health information available 
and used to inform the new health dialogue and disease 
control priorities, as we have shown here it can be, would 
be a massive missed opportunity for global health.
Contributors
CJLM, ADL, and RL prepared the fi rst draft. RL, MN, KF, SL, KS, ADL, 
and CJLM fi nalised the draft on the basis of comments from other 
authors and reviewer feedback. ADL and CJLM conceived the study and 
provided overall guidance. All other authors developed cause-specifi c 
models, reviewed results, provided guidance on the selection of key 
covariates, and reviewed the report.
Confl icts of interest
E R Dorsey has received consulting fees from Medtronic and Lundbeck and 
research support from Lundbeck and Prana Biotechnology. M Ezzati 
chaired a session and gave a talk at the World Cardiology Congress (WCC), 
with travel cost reimbursed by the World Heart Federation. At the WCC, he 
also gave a talk at a session organised by PepsiCo with no fi nancial or other 
renumeration. P J Hotez reports holding several positions: Dean, National 
School of Tropical Medicine, Baylor College of Medicine; Director, Sabin 
Vaccine Institute Texas Children’s Hospital Center for Vaccine 
Development; and President, Sabin Vaccine Institute.  He also is an 
inventor on several patents: 5,527,937 “Hookworm Anticoagulant”; 
5,753,787 “Nucleic Acids for Ancylostoma Secreted Proteins”; 7,303,752 B2 
“Hookworm vaccine”; 12/492,734 “Human Hookworm Vaccine”; 61/077,256 
“Multivalent Anthelminthic Vaccine”; and PCT-20100701/ 0.20.5.18 “Malaria 
Transmission blocking vaccine”. G A Mensah is a former employee of 
PepsiCo. F Perez-Ruiz was an adviser for Ardea, Menarini, Novartis, and 
Metabolex; was a member of the Speaker’s Bureau for Menarini, Novartis; 
an adviser for educational issues for Savient; led an investigation grants for 
the Spanish Health Ministry, Hospital de Cruces Rheumatology 
Association; and was principal investigator in clinical trials for Ardea.
Acknowledgments
We would like to thank the countless individuals who have contributed to 
the Global Burden of Disease 2010 Study in various capacities. We would 
also like to specifi cally acknowledge the important contribution to this 
work from multiple staff  members of the WHO. We also wish to thank the 
following organisations that hosted consultations during the fi nal stages of 
the analytic process, providing valuable feedback about the results and the 
data to improve the study’s fi ndings overall: Pan American Health 
Organisation; Eastern Mediterranean Regional Offi  ce of WHO; UNAIDS; 
Ministry of Health, Brazil; China Centers for Disease Control; and the 
University of Zambia. We would like to thank Cynthia Boschi Pinto for her 
input into the analyses and estimates. Finally, we would like to 
acknowledge the extensive support from all staff  members at the Institute 
for Health Metrics and Evaluation and specifi cally thank: James Bullard, 
Andrew Ernst, and Serkan Yalcin for their tireless support of the 
computational infrastructure required to produce the results; 
Linda A Ettinger for her expert administrative support and facilitating 
communication and coordination among the authors; Peter Speyer, 
Abigail McLain, Katherine Leach-Kemon, and Eden Stork for their 
Articles
2126 www.thelancet.com   Vol 380   December 15/22/29, 2012
persistent and invaluable work to gain access to and catalogue as much 
data as possible to inform the estimates; and Erin C Mullany for her 
systematic eff orts in organising drafts of papers, formatting 
correspondence with expert groups, and preparing the fi nal manuscript.
The following individuals would like to acknowledge various forms of 
institutional support. J P Abraham acknowledges the World Bank Global 
Road Safety Facility and Department of Global Health & Population, 
Harvard School of Public Health, and the WHO Violence and Injury 
Prevention. K Bhalla was supported by the World Bank Global Road Safety 
Facility for researcher salaries, to pay for many small projects in Africa to 
digitise secondary data sources, and supporting several gatherings of the 
injury expert group over the past 6 years. B Bikbov acknowledges the 
Moscow State University of Medicine and Dentistry, Moscow, Russia; 
Academician V I Shumakov Federal Research Centre of Transplantology 
and Artifi cial Organs, Moscow, Russia; and International Society of 
Nephrology. G L Birbeck has received research funding from the US NIH, 
the Dana Foundation, and the Doris Duke Charitable Foundation; she has 
also received travel grants from the WHO for related work. H Chen 
acknowledges his participation in this study was in part supported by the 
intramural research program of the NIH, the National Institute of 
Environmental Health Sciences. L E Coff eng received fi nancial support 
from the African Programme for Onchocerciasis Control (WHO/APOC) 
for work on onchocerciasis. M Cortinovis, F Gaspari, and N Perico 
acknowledge the International Society of Nephrology (ISN) on the behalf 
of the entire Genitourinary Expert Group. M Cross and L March 
acknowledge the University of Sydney (USYD); Institute of Bone and 
Joint Research, University of Sydney, Department of Rheumatology, Royal 
North Shore Hospital, St Leonards NSW 2065 Australia. N Dahodwala 
was supported by NIH grant K23 AG034236 and the Parkinson Council 
while working on this project. L Degenhardt is supported by an Australian 
NHMRC Senior Research Fellowship and funding to support work on 
illicit drug dependence was provided by the Australian National Drug and 
Alcohol Research Centre of the University of New South Wales, NSW, 
Australia. R Havmoeller is supported by a grant from the Swedish 
Research Council (#2011-1071). D Hoy was supported by the Bill & 
Melinda Gates Foundation and the Australian National Health and 
Medical Research Council. P J Hotez acknowledges grant support from 
several sources: the Bill & Melinda Gates Foundation regarding human 
hookworm vaccine through the Sabin Institute (Human Hookworm 
Vaccine Initiative 1 Human Hookworm Vaccine Initiative; Human 
Hookworm Vaccine Initiative 3 Clinical Development and Evaluation of 
the Na-GST-1 and Na-APR-1 Hookworm Vaccine Antigen); the National 
Institutes of Health (Product development of a membrane tetraspanin 
vaccine against schistosomiasis; RBD Recombinant Protein-based SARS 
Vaccine for Biodefense); and the Dutch Government (Product 
Development Support of the Human Hookworm Vaccine). K H Jacobsen 
was supported by the WHO for her work on Hepatitis A. B M Mayosi was 
funded by the Lily and Ernst Hausmann Research Trust. T R Merriman 
acknowledges the Health Research Council of New Zealand. D Ozgediz is 
grateful for the collaboration colleagues at Mulago Hospital and Makerere 
University in Kampala, Uganda. B Pahari would like to thank the 
Mario Negri Institute. U Sampson was funded in part by The 
Harold Amos Medical Faculty Development Award of the Robert Wood 
Johnson Foundation and The Vanderbilt Clinical and Translational 
Scholars Award. M Segui-Gomez’s participation was partly supported by 
funds of the European Center for Injury Prevention, Universidad de 
Navarra. E Smith acknowledges Department of Health and Ageing, 
Commonwealth Government of Australia, Institute of Bone and Joint 
Research (IBJR), University of Sydney (USYD), Department of 
Rheumatology, Royal North Shore Hospital, St Leonards NSW 2065 
Australia. L Rushton was supported by honorarium for board 
membership of the European Centre for Ecotoxicology and Toxicology of 
Chemicals; research grants to Imperial College London (as PI) from the 
European Chemical Industry Council (CEFIC) and CONCAWE 
(Conservation of Clean Air and Water Europe). P Yip was supported by a 
General Research Grant at the University of Hong Kong.
References
1 Murray CJL, Kulkarni SC, Ezzati M. Understanding the coronary 
heart disease versus total cardiovascular mortality paradox: 
a method to enhance the comparability of cardiovascular death 
statistics in the United States. Circulation 2006; 113: 2071–81.
2 Ruzicka LT, Lopez AD. The use of cause-of-death statistics for health 
situation assessment: national and international experiences. 
World Health Stat Q 1990; 43: 249–58.
3 Lopez AD. Causes of death in the industrialized and developing 
countries: estimates for 1985–1990. In: Disease Control Priorities in 
Developing Countries: Oxford Medical Publications, Oxford 
University Press, 1993: 15–30.
4 Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the 
dead and what they died from: an assessment of the global status 
of cause of death data. Bull World Health Organ 2005; 83: 171–77.
5 Lu T-H, Shih T-P, Lee M-C, Chou M-C, Lin C-K. Diversity in death 
certifi cation: a case vignette approach. J Clin Epidemiol 2001; 
54: 1086–93.
6 Abouzahr C. New estimates of maternal mortality and how to 
interpret them: choice or confusion? Reprod Health Matters 2011; 
19: 117–28.
7 Grassly NC, Morgan M, Walker N, et al. Uncertainty in estimates of 
HIV/AIDS: the estimation and application of plausibility bounds. 
Sex Transm Infect 2004; 80 (suppl 1): i31–38.
8 Cooper RS, Osotimehin B, Kaufman JS, Forrester T. Disease 
burden in sub-Saharan Africa: what should we conclude in the 
absence of data? Lancet 1998; 351: 208–10.
9 Hakulinen T, Hansluwka H, Lopez AD, Nakada T. Global and 
regional mortality patterns by cause of death in 1980. Int J Epidemiol 
1986; 15: 226–33.
10 Bulatao RA, Stephens PW. Global estimates and projections of 
mortality by cause, 1970–2015. Population and Human Resources 
Dept: the World Bank, 1992.
11 Lopez AD, Hull TH. A note on estimating the cause of death 
structure in high mortality populations. Popul Bull UN 1982; 
14: 66–70.
12 Murray CJL, Lopez AD. Evidence-based health policy—lessons 
from the Global Burden of Disease Study. Science 1996; 
274: 740–43.
13 WHO. The world health report 2000—Health systems: improving 
performance. Geneva: World Health Organization, 2000. http://
www.who.int/whr/2000/en/whr00_en.pdf (accessed July 9, 2012).
14 WHO. The world health report 2001—Mental health: new 
understanding, new hope. Geneva: World Health Organization, 
2001. http://www.who.int/whr/2001/en/whr01_en.pdf (accessed 
June 25, 2012).
15 WHO. The world health report 2002—Reducing risks, promoting 
healthy life. Geneva: World Health Organization, 2002. http://www.
who.int/whr/2002/en/whr02_en.pdf (accessed July 9, 2012).
16 Mathers C, Fat DM, Boerma JT, WHO. The Global Burden of 
Disease: 2004 Update. World Health Organization, 2008.
17 WHO. Disease and injury regional estimates. Cause-specifi c 
mortality: regional estimates for 2008. World Health 
Organization. http://www.who.int/healthinfo/global_burden_
disease/estimates_regional/en/index.html (accessed July 10, 
2012).
18 Bryce J, Boschi-Pinto C, Shibuya K, Black RE, and the WHO Child 
Health Epidemiology Reference Group. WHO estimates of the 
causes of death in children. Lancet 2005; 365: 1147–52.
19 Black RE, Cousens S, Johnson HL, et al, and the Child Health 
Epidemiology Reference Group of WHO and UNICEF. Global, 
regional, and national causes of child mortality in 2008: 
a systematic analysis. Lancet 2010; 375: 1969–87.
20 Liu L, Johnson HL, Cousens S, et al, and the Child Health 
Epidemiology Reference Group of WHO and UNICEF. Global, 
regional, and national causes of child mortality: an updated 
systematic analysis for 2010 with time trends since 2000. 
Lancet 2012; 379: 2151–61.
21 Hill K, Thomas K, AbouZahr C, et al. Estimates of maternal 
mortality worldwide between 1990 and 2005: an assessment of 
available data. Lancet 2007; 370: 1311–19.
22 Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 
181 countries, 1980–2008: a systematic analysis of progress 
towards Millennium Development Goal 5. Lancet 2010; 
375: 1609–23.
23 Lozano R, Wang H, Foreman KJ, et al. Progress towards 
Millennium Development Goals 4 and 5 on maternal and child 
mortality: an updated systematic analysis. Lancet 2011; 
378: 1139–65.
Articles
www.thelancet.com   Vol 380   December 15/22/29, 2012 2127
24 UNFPA, UNICEF, WHO, World Bank. Trends in Maternal 
Mortality: 1990 to 2010. Geneva: World health Organization, 2012. 
http://www.unfpa.org/webdav/site/global/shared/documents/
publications/2012/Trends_in_maternal_mortality_A4-1.pdf 
(accessed June 7, 2012).
25  Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality 
between 1980 and 2010: a systematic analysis. Lancet 2012; 379: 413–31.
26 WHO. World malaria report. Geneva: World Health Organization, 
2011. http://www.who.int/malaria/world_malaria_
report_2011/9789241564403_eng.pdf (accessed Jul 2, 2012).
27 Glaziou P, Floyd K, Korenromp EL, et al. Lives saved by tuberculosis 
control and prospects for achieving the 2015 global target for reducing 
tuberculosis mortality. Bull World Health Organ 2011; 89: 573–82.
28 WHO. Global tuberculosis control 2011. Geneva: World Health 
Organization, 2011. http://www.who.int/entity/tb/publications/
global_report/2011/gtbr11_full.pdf (accessed July 2, 2012).
29 UNAIDS. Global report: UNAIDS report on the global aids epidemic. 
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010. 
http://www.unaids.org/globalreport/documents/20101123_
GlobalReport_full_en.pdf (accessed June 29, 2012).
30 WHO. Global status report on road safety 2009. Geneva: 
World Health Organization, 2009. http://whqlibdoc.who.int/
publications/2009/9789241563840_eng.pdf (accessed June 29, 2012).
31 Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and 
cervical cancer in 187 countries between 1980 and 2010: a systematic 
analysis. Lancet 2011; 378: 1461–84.
32 Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 
2008. Int J Cancer 2010; 127: 2893–917.
33 Roglic G, Unwin N, Bennett PH, et al. The burden of mortality 
attributable to diabetes: realistic estimates for the year 2000. 
Diabetes Care 2005; 28: 2130–35.
34 Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global 
measles mortality reduction goal: results from a model of 
surveillance data. Lancet 2012; 379: 2173–78.
35 O’Brien KL, Wolfson LJ, Watt JP, et al, and the Hib and 
Pneumococcal Global Burden of Disease Study Team. Burden of 
disease caused by Streptococcus pneumoniae in children younger 
than 5 years: global estimates. Lancet 2009; 374: 893–902.
36 Salomon JA, Murray CJL. The Epidemiologic Transition Revisited: 
Compositional Models for Causes of Death by Age and Sex. 
Popul Dev Rev 2002; 28: 205–28.
37 Rajaratnam JK, Marcus JR, Flaxman AD, et al. Neonatal, 
postneonatal, childhood, and under-5 mortality for 187 countries, 
1970–2010: a systematic analysis of progress towards Millennium 
Development Goal 4. Lancet 2010; 375: 1988–2008.
38 Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of 
death: an integrated approach using CODEm. Popul Health Metr 
2012; 10: 1.
39 Murray CJL, Ezzati M, Flaxman AD, et al. The Global Burden of 
Disease Study 2010: design, defi nitions, and metrics. Lancet 2012; 
380: 2063–66.
40 Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specifi c and sex-
specifi c mortality in 187 countries, 1970–2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet 2012; 380: 2071–94.
41 UN Offi  ce on Drugs and Crimes. United Nations surveys on crime 
trends and the operations of criminal justice systems. http://www.
unodc.org/unodc/en/data-and-analysis/United-Nations-Surveys-on-
Crime-Trends-and-the-Operations-of-Criminal-Justice-Systems.html 
(accessed June 7, 2012).
42 Murray CJL, Lopez AD, Barofsky JT, Bryson-Cahn C, Lozano R. 
Estimating population cause-specifi c mortality fractions from 
in-hospital mortality: validation of a new method. PLoS Med 2007; 
4: e326.
43 Murray CJL, Lopez AD. Estimating causes of death: new methods and 
global and regional application for 1990. In: Murray CJL, Lopez AD, 
eds. Global Burden of Disease and Injury Series. The global burden 
of disease: a comprehensive assessment of mortality and disability 
from diseases, injuries, and risk factors in 1990 and projected to 2020. 
Boston: Harvard School of Public Health, on behalf of the World 
Health Organization and the World Bank, 1996: 117–200.
44 Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the 
causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol 
2006; 35: 706–18.
45 Kulkarni SC, Levin-Rector A, Ezzati M, Murray CJ. Falling behind: 
life expectancy in US counties from 2000 to 2007 in an international 
context. Popul Health Metr 2011; 9: 16.
46 Murray CJL, Rajaratnam JK, Marcus J, Laakso T, Lopez AD. What 
can we conclude from death registration? Improved methods for 
evaluating completeness. PLoS Med 2010; 7: e1000262.
47 Gakidou E, King G. Death by survey: estimating adult mortality 
without selection bias from sibling survival data. Demography 2006; 
43: 569–85.
48 Sullivan J. An assessment of the credibility of child mortality 
declines estimated from DHS mortality rates., UNICEF (Working 
Draft; Revision 1, 10/29/08).
49 Murray CJL, Lopez AD. The global burden of disease: 
a comprehensive assessment of mortality and disability from 
diseases, injuries, and risk factors in 1990 and projected to 2020. 
Boston: Harvard School of Public Health, on behalf of the World 
Health Organization and the World Bank, 1996.
50 Naghavi M, Makela S, Foreman K, O’Brien J, Pourmalek F, 
Lozano R. Algorithms for enhancing public health utility of national 
causes-of-death data. Popul Health Metr 2010; 8: 9.
51 Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ. 
Improving the public health utility of global cardiovascular mortality 
data: the rise of ischemic heart disease. Popul Health Metr 2011; 9: 8.
52 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability 
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a 
systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2163–96.
53 Schulz KF, Cates W Jr, O’Mara PR. Pregnancy loss, infant death, 
and suff ering: legacy of syphilis and gonorrhoea in Africa. 
Genitourin Med 1987; 63: 320–25.
54 WHO. The global elimination of congenital syphilis: rationale and 
strategy for action. http://whqlibdoc.who.int/publications/2007
/ 9789241595858_eng.pdf (accessed July 6, 2012).
55 Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths 
from pertussis are underestimated in England. Arch Dis Child 2002; 
86: 336–38.
56 Anker M. The eff ect of misclassifi cation error on reported 
cause-specifi c mortality fractions from verbal autopsy. 
Int J Epidemiol 1997; 26: 1090–96.
57 Birnbaum JK, Murray CJ, Lozano R. Exposing misclassifi ed HIV/AIDS 
deaths in South Africa. Bull World Health Organ 2011; 89: 278–85.
58 Murray C, Lopez AD, Wang H. Mortality estimation for national 
populations: methods and applications. Seattle, WA: University of 
Washington Press, 2012.
59 Gleditsch N, Wallensteen P, Eriksson M, Sollenberg M, Strand H. 
Armed confl ict 1946–2001: a new dataset. J Peace Res 2002; 39: 615–37.
60 Centre for Research on the Epidemiology of Disasters (CRED), 
Offi  ce of US Foreign Disaster Assistance (OFDA). EM-DAT: 
The OFDA/CRED international disaster database. Brussels, 
Belgium, Université Catholique de Louvain. http://www.emdat.be/
database (accessed May 16, 2012).
61 Population Prospects W. The 2010 revision. New York, United 
Nations, United Nations, Department of Economic and Social 
Aff airs, Population Division, 2011.
62 Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, 
Inoue M. Age standardization of rates: a new who standard. 
Geneva: World Health Organization, 2001. http://www.who.int/
healthinfo/paper31.pdf (accessed June 29, 2012).
63 Logan WPD. Mortality in England and Wales from 1848 to 1947. 
Popul Stud 1950; 4: 132–78.
64 Marks G, Burney P. Diseases of the respiratory system. In: The 
health of adult Britain 1841–1994. Stationery Offi  ce, 1997.
65 Adair T, Damian H, Dettrick Z, Lopez AD. 100 years of chronic 
obstructive pulmonary disease (COPD) mortality in Australia: 
the role of tobacco consumption. Int J Tuberc Lung Dis 2012; 
16: 1699–1705.
66 Choprapawon C, Porapakkham Y, Sablon O, Panjajaru R, 
Jhantharatat B. Thailand’s national death registration reform: 
verifying the causes of death between July 1997 and December 1999. 
Asia Pac J Public Health 2005; 17: 110–16.
67 Porapakkham Y, Rao C, Pattaraarchachai J, et al. Estimated causes 
of death in Thailand, 2005: implications for health policy. 
Popul Health Metr 2010; 8: 14.
Articles
2128 www.thelancet.com   Vol 380   December 15/22/29, 2012
68 Lozano R, Lopez AD, Atkinson C, Naghavi M, Flaxman AD, 
Murray CJ, and the Population Health Metrics Research 
Consortium (PHMRC). Performance of physician-certifi ed verbal 
autopsies: multisite validation study using clinical diagnostic gold 
standards. Popul Health Metr 2011; 9: 32.
69 Bates M, O’Grady J, Mudenda V, Shibemba A, Zumla A. New global 
estimates of malaria deaths. Lancet 2012; 380: 560–61.
70 Lynch M, Korenromp E, Eisele T, et al. New global estimates of 
malaria deaths. Lancet 2012; 380: 559.
71 Shah NK, Kumar A, Valecha N. New global estimates of malaria 
deaths. Lancet 2012; 380: 560.
72 White NJ, Dondorp AM, Faiz A, Mishra S, Hien TT. New global 
estimates of malaria deaths. Lancet 2012; 380: 559–60.
73 Project Description. Global Enterics Mutli-Center Study (GEMS): 
University of Maryland School of Medicine. http://medschool.
umaryland.edu/GEMS/ (accessed June 7, 2012).
74 WHO. Estimated rotavirus deaths for children under 5 years of age: 
2008, 453 000. Geneva: World Health Organization, 2012. http://
www.who.int/immunization_monitoring/burden/rotavirus_
estimates/en/index.html (accessed July 6, 2012).
75 Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower 
respiratory infections due to respiratory syncytial virus in young 
children: a systematic review and meta-analysis. Lancet 2010; 
375: 1545–55.
76 Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by 
Haemophilus infl uenza type b in children younger than 5 years: 
global estimates. Lancet 2009; 374: 903–11.
77 Almirall J, Boixeda R, Bolíbar I, et al, and the GEMPAC Study 
Group. Diff erences in the etiology of community-acquired 
pneumonia according to site of care: a population-based study. 
Respir Med 2007; 101: 2168–75.
78 Díaz A, Barria P, Niederman M, et al. Etiology of 
community-acquired pneumonia in hospitalized patients in chile: 
the increasing prevalence of respiratory viruses among classic 
pathogens. Chest 2007; 131: 779–87.
79 Elliot AJ, Fleming DM. Infl uenza and respiratory syncytial virus in 
the elderly. Expert Rev Vaccines 2008; 7: 249–58.
80 Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 
Respiratory syncytial virus infection in elderly and high-risk adults. 
N Engl J Med 2005; 352: 1749–59.
81 Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired 
pneumonia in hospitalized patients in northern Israel. 
Isr Med Assoc J 2010; 12: 477–82.
82 Köksal I, Ozlü T, Bayraktar O, et al, and the TUCAP Study Group. 
Etiological agents of community-acquired pneumonia in adult 
patients in Turkey; a multicentric, cross-sectional study. 
Tuberk Toraks 2010; 58: 119–27.
83 Maruyama T, Niederman MS, Kobayashi T, et al. A prospective 
comparison of nursing home-acquired pneumonia with 
hospital-acquired pneumonia in non-intubated elderly. Respir Med 
2008; 102: 1287–95.
84 Maruyama T, Gabazza EC, Morser J, et al. Community-acquired 
pneumonia and nursing home-acquired pneumonia in the very 
elderly patients. Respir Med 2010; 104: 584–92.
85 Levine OS, O’Brien KL, Deloria-Knoll M, et al. The Pneumonia 
Etiology Research for Child Health Project: a 21st century 
childhood pneumonia etiology study. Clin Infect Dis 2012; 
54 (suppl 2): S93–101.
86 Ganyaglo GYK, Hill WC. A 6-year (2004–2009) review of maternal 
mortality at the Eastern Regional Hospital, Koforidua, Ghana. 
Semin Perinatol 2012; 36: 79–83.
87 Almerie MQ, Matar HE, Almerie Y. A 20-year (1989–2008) audit of 
maternal mortality in Damascus, Syria. Int J Gynaecol Obstet 2011; 
112: 70–71.
88 United Nations Millennium Development Goals. http://www.
un.org/millenniumgoals/reports.shtml (accessed June 29, 2012).
89 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO 
analysis of causes of maternal death: a systematic review. Lancet 
2006; 367: 1066–74.
90 Waage J, Banerji R, Campbell O, et al. The Millennium 
Development Goals: a cross-sectoral analysis and principles for goal 
setting after 2015 Lancet and London International Development 
Centre Commission. Lancet 2010; 376: 991–1023.
91 Beaglehole R, Bonita R, Horton R, et al, and the Lancet NCD Action 
Group, and the NCD Alliance. Priority actions for the 
non-communicable disease crisis. Lancet 2011; 377: 1438–47.
92 Beaglehole R, Yach D. Globalisation and the prevention and control 
of non-communicable disease: the neglected chronic diseases of 
adults. Lancet 2003; 362: 903–08.
93 Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic 
non-communicable diseases. Nature 2007; 450: 494–96.
94 Nugent RA, Yach D, Feigl AB. Non-communicable diseases and the 
Paris Declaration. Lancet 2009; 374: 784–85.
95 Yach D. Nutritional change is not a simple answer to 
non-communicable diseases. BMJ 2011; 343: d5097.
96 Geneau R, Stuckler D, Stachenko S, et al. Raising the priority of 
preventing chronic diseases: a political process. Lancet 2010; 
376: 1689–98.
97 Mock C, Joshipura M, Arreola-Risa C, Quansah R. An estimate of 
the number of lives that could be saved through improvements in 
trauma care globally. World J Surg 2012; 36: 959–63.
98 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic 
kidney disease and the risks of death, cardiovascular events, and 
hospitalization. N Engl J Med 2004; 351: 1296–305.
99 Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of 
burden of disease and injury attributable to 67 risk factors and risk 
factor clusters in 21 regions, 1990–2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–60.
100 Murray CJL, King G, Lopez AD, Tomijima N, Krug EG. Armed 
confl ict as a public health problem. BMJ 2002; 324: 346–49.
101 Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral 
antischistosomal therapy in the spread of hepatitis C virus in Egypt. 
Lancet 2000; 355: 887–91.
102 Zatoński WA, Sulkowska U, Mańczuk M, et al. Liver cirrhosis 
mortality in Europe, with special attention to Central and Eastern 
Europe. Eur Addict Res 2010; 16: 193–201.
103 WHO. Global health observatory data repository mortality, road 
traffi  c deaths. Geneva: World Health Organization, 2007. 
http://apps.who.int/ghodata/?vid=51210# (accessed July 5, 2012).
104 Roulson J, Benbow EW, Hasleton PS. Discrepancies between 
clinical and autopsy diagnosis and the value of post mortem 
histology; a meta-analysis and review. Histopathology 2005; 
47: 551–59.
105 Sonderegger-Iseli K, Burger S, Muntwyler J. Diagnostic errors in 
three medical eras: a necropsy study. Lancet 2000; 355: 2027–31.
106 Autopsy as an outcome and performance measure: summary—
AHRQ Evidence Report Summaries— NCBI Bookshelf. http://
www.ncbi.nlm.nih.gov/books/NBK11951/ (accessed June 29, 2012).
107 Verbal autopsy: innovations, applications, opportunities—
Improving cause of death measurement. Popul Health Metr 2011; 
9: 18–50.
108 Flaxman AD, Vahdatpour A, Green S, James SL, Murray CJ, and the 
Population Health Metrics Research Consortium (PHMRC). Random 
forests for verbal autopsy analysis: multisite validation study using 
clinical diagnostic gold standards. Popul Health Metr 2011; 9: 29.
109 Murray CJ, James SL, Birnbaum JK, Freeman MK, Lozano R, 
Lopez AD, and the Population Health Metrics Research Consortium 
(PHMRC). Simplifi ed symptom pattern method for verbal autopsy 
analysis: multisite validation study using clinical diagnostic gold 
standards. Popul Health Metr 2011; 9: 30.
110 James SL, Flaxman AD, Murray CJ, and the Population Health 
Metrics Research Consortium (PHMRC). Performance of the Tariff  
Method: validation of a simple additive algorithm for analysis of 
verbal autopsies. Popul Health Metr 2011; 9: 31.
111 Murray CJ, Lopez AD, Black R, et al. Population Health Metrics 
Research Consortium gold standard verbal autopsy validation study: 
design, implementation, and development of analysis datasets. 
Popul Health Metr 2011; 9: 27.
112 WHO. Health Metrics Network (HMN). Geneva: World Health 
Organization. http://www.who.int/healthmetrics/en/ (accessed 
July 10, 2012).
